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A B S T R A C T
Background
Surgical excision by removal of the head of the pancreas to decompress the obstructed ducts is one of the treatment options for people
with symptomatic chronic pancreatitis. Surgical excision of the head of the pancreas can be performed by excision of the duodenum
along with the head of the pancreas (pancreaticoduodenectomy (PD)) or without excision of the duodenum (duodenum-preserving
pancreatic head resection (DPPHR)). There is currently no consensus on the method of pancreatic head resection in people with
chronic pancreatitis.
Objectives
To assess the benefits and harms of duodenum-preserving pancreatic head resection versus pancreaticoduodenectomy in people with
chronic pancreatitis for whom pancreatic resection is considered the main treatment option.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index Ex-
panded, and trials registers to June 2015 to identify randomised trials. We also searched the references of included trials to identify
further trials.
Selection criteria
We considered only randomised controlled trials (RCT) performed in people with chronic pancreatitis undergoing pancreatic head
resection, irrespective of language, blinding, or publication status, for inclusion in the review.
Data collection and analysis
Two review authors independently identified trials and extracted data. We calculated the risk ratio (RR), mean difference (MD), rate
ratio (RaR), or hazard ratio (HR) with 95% confidence intervals (CI) based on an available-case analysis.
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Main results
Five trials including 292 participants met the inclusion criteria for the review. After exclusion of 23 participants mainly due to pancreatic
cancer or because participants did not receive the planned treatment, a total of 269 participants (with symptomatic chronic pancreatitis
involving the head of pancreas and requiring surgery) were randomly assigned to receive DPPHR (135 participants) or PD (134
participants). The trials did not report the American Society of Anesthesiologists (ASA) status of the participants. All the trials were
single-centre trials and included people with and without obstructive jaundice and people with and without duodenal stenosis but did
not report data separately for those with and without jaundice or those with and without duodenal stenosis. The surgical procedures
compared in the five trials included DPPHR (Beger or Frey procedures, or wide local excision of the head of the pancreas) and PD
(pylorus-preserving pancreaticoduodenectomy or Whipple procedure). The participants were followed up for various periods of time
ranging from one to 15 years. The trials were at unclear or high risk of bias. The overall quality of evidence was low or very low.
The differences in short-term mortality (up to 90 days after surgery) (RR 2.89, 95% CI 0.31 to 26.87; 369 participants; 5 studies;
DPPHR: 2/135 (1.5%) versus PD: 0/134 (0%); very low quality evidence) or long-termmortality (maximal follow-up) (HR 0.65, 95%
CI 0.31 to 1.34; 229 participants; 4 studies; very low quality evidence), medium-term (three months to five years) (only a narrative
summary was possible; 229 participants; 4 studies; very low quality evidence), or long-term quality of life (more than five years) (MD
8.45, 95% CI -0.27 to 17.18; 101 participants; 2 studies; low quality evidence), proportion of people with adverse events (RR 0.55,
95% CI 0.22 to 1.35; 226 participants; 4 studies; DPPHR: 23/113 (adjusted proportion 20%) versus PD: 41/113 (36.3%); very low
quality evidence), number of people with adverse events (RaR 0.95, 95% CI 0.43 to 2.12; 43 participants; 1 study; DPPHR: 12/22
(54.3 events per 100 participants) versus PD: 12/21 (57.1 events per 100 participants); very low quality evidence), proportion of people
employed (maximal follow-up) (RR 1.54, 95% CI 1.00 to 2.37; 189 participants; 4 studies; DPPHR: 65/98 (adjusted proportion
69.4%) versus PD: 41/91 (45.1%); low quality evidence), incidence proportion of diabetes mellitus (maximum follow-up) (RR 0.78,
95% CI 0.50 to 1.22; 269 participants; 5 studies; DPPHR: 25/135 (adjusted proportion 18.6%) versus PD: 32/134 (23.9%); very
low quality evidence), and prevalence proportion of pancreatic exocrine insufficiency (maximum follow-up) (RR 0.83, 95% CI 0.68 to
1.02; 189 participants; 4 studies; DPPHR: 62/98 (adjusted proportion 62.0%) versus PD: 68/91 (74.7%); very low quality evidence)
were imprecise. The length of hospital stay appeared to be lower with DPPHR compared to PD and ranged between a reduction of
one day and five days in the trials (208 participants; 4 studies; low quality evidence). None of the trials reported short-term quality of
life (four weeks to three months), clinically significant pancreatic fistulas, serious adverse events, time to return to normal activity, time
to return to work, and pain scores using a visual analogue scale.
Authors’ conclusions
Low quality evidence suggested that DPPHR may result in shorter hospital stay than PD. Based on low or very low quality evidence,
there is currently no evidence of any difference in themortality, adverse events, or quality of life betweenDPPHR and PD. However, the
results were imprecise and further RCTs are required on this topic. Future RCTs comparing DPPHR with PD should report the severity
as well as the incidence of postoperative complications and their impact on patient recovery. In such trials, participant and observer
blinding should be performed and the analysis should be performed on an intention-to-treat basis to decrease the bias. In addition
to the short-term benefits and harms such as mortality, surgery-related complications, quality of life, length of hospital stay, return to
normal activity, and return to work, future trials should consider linkage of trial participants to health databases, social databases, and
mortality registers to obtain the long-term benefits and harms of the different treatments.
P L A I N L A N G U A G E S U M M A R Y
Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Review question
Should the duodenum (upper part of the small intestine) be removed while removing the pancreatic head in people with symptoms of
chronic pancreatitis?
Background
The pancreas is an organ in the belly (abdomen) that secretes several digestive enzymes into the pancreatic ductal system (tubes that
carry the pancreatic juice secreted by the pancreatic cells), which empties into the small bowel. It also comprises the Islets of Langerhans,
which secrete several hormones including insulin (helps regulate blood sugar). Chronic pancreatitis is long-standing and progressive
inflammation of the pancreas resulting in destruction and replacement of pancreatic material (tissue) with fibrous tissue. This may
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lead to digestive enzyme deficiency (shortage) and insulin deficiency leading to diabetes (a lifelong condition that causes a person’s
blood sugar level to become too high). Alcohol is considered the main cause of acute pancreatitis. Chronic abdominal pain is the major
symptom of chronic pancreatitis. The pain is usually in the upper abdomen and is described as deep, penetrating, and radiating to the
back. Various theories exist about the reason for pain in chronic pancreatitis. One of the theories is that the disease process obstructs the
pancreatic duct. So, surgery to remove the head of the pancreas (the part that is encircled by the duodenum) is recommended for some
people with pain uncontrolled with medicines. Major complications of surgery include deaths (mortality) and re-operations. However,
it is unclear whether the duodenum should be excised (surgically removed) along with the head of the pancreas. Thus, we searched for
existing studies on the topic. We included all randomised controlled trials (clinical studies where people are randomly put into one of
two or more treatment groups) whose results were reported to 22 June 2015.
Study characteristics
Five trials including 292 participants met the inclusion criteria for the review. After exclusion of 23 participants due to various reasons,
269 participants (with symptomatic chronic pancreatitis involving the head of pancreas and undergoing surgery) received duodenum-
preserving pancreatic head resection (DPPHR) (head of pancreas is removed without removing the duodenum) (135 participants)
or pancreaticoduodenectomy (PD) (head of pancreas is removed along with the duodenum encircling it) (134 participants) in these
trials. The trials did not report anaesthetic risk (likelihood of complications due to anaesthesia) of the participants. All the trials were
single-centre (occurred in only one clinical or medical centre). The participants were observed (followed up) for various periods of time
ranging from one to 15 years. All the trials were at high risk of bias.
Key results
The differences in short-term (up to 90 days after surgery) or long-term (maximal follow-up) mortality, medium-term (three months
to five years) or long-term (more than five years) quality of life, percentage and number of people with side effects, percentage of people
employed (maximal follow-up), percentage of people who developed diabetes (maximum follow-up), and percentage of people with
pancreatic digestive enzyme deficiency (maximum follow-up) were imprecise. The length of hospital stay appeared to be lower with
DPPHR compared to PD and ranged between a reduction of one and five days in the trials. None of the trials reported short-term
quality of life (four weeks to three months), clinically significant pancreatic fistulas (abnormal drainage of pancreatic juice internally or
externally), serious side effects, time to return to normal activity, time to return to work, and pain scores using a visual analogue scale
(a measurement tool to compare subjective measures such as pain that cannot be directly measured; pain levels between 0 and 10 or 0
and 100).
Quality of the evidence
The quality of evidence was low or very low. As a result, further studies are required on this topic. Such studies should report the
severity of postoperative complications and their impact on patient recovery and should include all the trial participants in the results.
In addition to the short-term benefits and harms such as mortality, surgery-related complications, quality of life, length of hospital
stay, return to normal activity, and return to work, future trials should consider linkage of trial participants to health databases, social
databases, and mortality registers to obtain the long-term benefits and harms of the different treatments.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: people requiring surgery for chronic pancreatitis
Setting: surgical unit
Intervention: duodenum-preserving pancreatic resection
Comparison: pancreaticoduodenectomy
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with pancreatico-
duodenectomy
Risk with duodenum-
preserving pancreatic
resection
Short-term mortality 10 per 1000 29 per 1000
(3 to 269)
RR 2.89
(0.31 to 26.87)
269
(5 RCTs)
⊕©©©
Very low1,2
-
Long-term mortality 281 per 1000 193 per 1000
(97 to 357)
HR 0.65
(0.31 to 1.34)
229
(4 RCTs)
⊕©©©
Very low1,3,4
-
Serious adverse events - - - - - None of the included
studies reported seri-
ous adverse events.
Summary of findings 2
summarises non-serious
adverse events
Quality of life (3 months
to 5 years)
The median quality of life
ranged between 28.6 and
67
The median quality of life
ranged between 67 and
85.7
- 146
(4 RCTs)
⊕©©©
Very low1,5
EORTC QLQ-C30 global
health value (higher
means better)
Quality of life (>5 years) The mean quality of life
(>5 years) was 58
The mean quality of life
(> 5 years) in the inter-
vention group was 8.45
more (0.27 fewer to 17.
18 more)
- 101
(2 RCTs)
⊕⊕©©
Low1
EORTC QLQ-C30 global
health value (higher
means better)
4
D
u
o
d
e
n
u
m
-p
re
se
rv
in
g
p
a
n
c
re
a
tic
re
se
c
tio
n
v
e
rsu
s
p
a
n
c
re
a
tic
o
d
u
o
d
e
n
e
c
to
m
y
fo
r
c
h
ro
n
ic
p
a
n
c
re
a
titis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
None of the trials reported the following outcomes: quality of life (4 weeks to 3 months), clinically significant pancreatic fistulas, serious adverse events, time to return to normal activity, time
to return to work, and pain scores using a visual analogue scale
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group (mean control group proportion for all outcomes except short-
term mortality where an assumed risk of 1% was used as there was no short-term mortality in the control group in the trials included in this review) and the relative effect of the intervention
(and its 95% CI).
CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 The trial(s) was/were of unclear or high risk of bias.
2 Although the event was a rare event, the confidence intervals were wide even when absolute measures were used. The sample size
was small.
3 The I2 value was high and there was lack of overlap of confidence intervals.
4 The confidence intervals were wide and the sample size was small.
5 There was inconsistency in the results.
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B A C K G R O U N D
Description of the condition
Please see the glossary of terms in Appendix 1.
The pancreas is an abdominal organ that secretes several digestive
enzymes into the pancreatic ductal system, which empties into
the small bowel. It also comprises the Islets of Langerhans, which
secrete several hormones including insulin (NCBI 2014). Chronic
pancreatitis is long-standing and progressive inflammation of the
pancreas resulting in destruction and replacement of pancreatic
tissue with fibrous tissue (structural deformity) (Braganza 2011).
This may lead to the functional deformity of exocrine pancreatic
insufficiency and endocrine pancreatic insufficiency (diabetes) (
Braganza 2011). Although previously considered as distinct from
acute pancreatitis (since the pancreas returns to normal after an
attack of acute pancreatitis), chronic pancreatitis is now considered
to belong to the spectrum of pancreatitis disorders that include
acute pancreatitis and acute recurrent pancreatitis, because of the
overlapping aetiology and symptoms (Braganza 2011).
The annual incidence of chronic pancreatitis ranges from1.5 to 7.9
per 100,000 population (Dite 2001; Dominguez-Munoz 2014;
Joergensen 2010; Spanier 2013; Yadav 2011). The prevalence of
chronic pancreatitis ranges from 17 to 49 per 100,000 population
(Dominguez-Munoz 2014; Joergensen 2010; Yadav 2011). The
annual mortality rate attributable to chronic pancreatitis is around
one to four per million people (Dominguez-Munoz 2014; Spanier
2013). Alcohol is the main cause of chronic pancreatitis (Dite
2001; Joergensen 2010; Yadav 2011). Other causes include smok-
ing; drugs such as valproate, thiazide, and oestrogens; other predis-
posing metabolic disorders, and diseases such as hypercalcaemia,
hyperparathyroidism, and chronic renal failure; infections such as
human immunodeficiency virus (HIV) and mumps; genetic mu-
tations such as SPINK1 or CFTR mutations; obstruction of the
main pancreatic duct due to cancer, scarring post ERCP (endo-
scopic retrograde cholangiopancreatography) or after an attack of
severe pancreatitis; recurrent pancreatitis; autoimmune pancreati-
tis; gallstones; and idiopathic pancreatitis (including tropical pan-
creatitis) (Braganza 2011; Dominguez-Munoz 2014; Joergensen
2010). The reasons for these causes to result in chronic pancre-
atitis are poorly understood and various theories have been pro-
posed (Braganza 2011). Increasing age and male gender are associ-
ated with a higher incidence and prevalence of chronic pancreatitis
(Joergensen 2010; Spanier 2013; Yadav 2011).
While histopathological examination of a specimen of pancreas
obtained by wedge biopsy or excision provides the definitive diag-
nosis of chronic pancreatitis, this is not practical (Braganza 2011),
unless the person is undergoing surgery. Invasive methods, such
as reduction of bicarbonate in duodenal aspirate after stimula-
tion with cholecystokinin or its analogue caerulein and ductal
abnormalities on ERCP, are not available routinely or cannot be
recommended routinely in people with chronic abdominal pain
(Braganza 2011). Secretin-enhanced magnetic resonance cholan-
giopancreatography (MRCP), endoscopic ultrasound (EUS), and
computed tomography (CT) scans are the other tests that may be
used for the diagnosis of chronic pancreatitis. CT scan, MRCP,
and EUS are the common tests used in the diagnostic algorithm
of chronic pancreatitis (Braganza 2011).
Various criteria have beenused for the classificationof chronic pan-
creatitis. Some of these are Ammann’s criteria (Ammann 1997),
the M-ANNHEIM criteria (named after the first letters of the
causes of pancreatitis) (Schneider 2007), the revised Japanese clini-
cal diagnostic criteria (Shimosegawa 2010), theManchester classi-
fication (Bagul 2006), and the Heidelberg criteria (Buchler 2009).
The presence of so many classifications is clear evidence of the
lack of consensus among experts about the classification of chronic
pancreatitis. The validity of these different criteria in terms of re-
producibility and implications has not been compared in order
to allow the recommendation of one classification system over
another. In general, the criteria for classification of chronic pan-
creatitis include one or more of the following features: chronic
abdominal pain, exocrine pancreatic insufficiency (pancreatic en-
zyme deficiency that leads to indigestion of food and is manifested
clinically by steatorrhoea, bloating, and excessive flatulence or es-
tablished by decreased stool elastase), calcifications in the pan-
creas, pancreatic ductal abnormalities, and histopathological diag-
nosis. In addition to the symptoms mentioned above, people may
also develop symptoms related to complications associated with
chronic pancreatitis, such as diabetes, pancreatic pseudocysts, and
biliary obstruction (Braganza 2011).
Chronic abdominal pain is the major manifestation of chronic
pancreatitis. The pain is usually in the upper abdomen and is
usually described as deep, penetrating, and radiating to the back
(Fasanella 2007). Various theories exist as to the pathogenesis of
pain in people with chronic pancreatitis. The major theories are
pancreatic duct hypertension caused by calcification and fibro-
sis resulting from inflammation; increased pancreatic tissue pres-
sure due to fibrosis of the peripancreatic capsule and parenchyma;
neural pain; pain due to bile duct and duodenal stenosis re-
sulting from pancreatic fibrosis; and pain resulting from pancre-
atic exocrine insufficiency (Di Sebastiano 2004; Fasanella 2007).
There are various theories for the origin of pain in chronic pan-
creatitis, therefore various treatments have been proposed for its
management, including surgical excision (please see Description
of the intervention; How the intervention might work), surgi-
cal drainage (Puestow’s procedure), pancreatic enzyme supple-
mentation (D’Haese 2014), somatostatin analogue octreotide
(Malfertheiner 1995), pregabalin (Olesen 2011), coeliac plexus
blocks and neurolysis (Puli 2009), and thoracic splanchnicectomy
(division of thoracic splanchnic nerves that carry the sympathetic
and sensory fibres from the abdominal organs including the pan-
creas) (Bradley 2003). Other treatments, such as antioxidants, are
aimed at preventing the oxidative damage that plays a role in the
pathogenesis of chronic pancreatitis (Ahmed Ali 2014). There is
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no consensus among experts about the selection of people with
chronic pancreatitis for surgical management, but pain and com-
plications are the major indications (Shah 2009).
Description of the intervention
Surgical excision can be performed by pancreaticoduodenectomy
(PD) (the standardWhipple procedure or pylorus-preserving pan-
creaticoduodenectomy (PPPD), where the pancreas head along
with duodenum and distal end of the bile duct, which drains into
the duodenum, are resected) or by duodenum-preserving pancre-
atic head resection (DPPHR) (Bachmann 2010; Shah 2009). PD
involves excision of the head of the pancreas and duodenum. The
two major types are the classical Whipple procedure and the py-
lorus-preserving pancreatoduodenectomy (Bachmann 2010; Shah
2009). DPPHR involves resection of the pancreatic head with-
out excision of duodenum. This avoids the necessity for gastroen-
teric and biliary enteric anastomoses. The two major types are
Beger procedure and Frey procedure (Bachmann 2010). Frey pro-
cedure involves a drainage procedure to anastomose the duct in
the pancreatic remnant to the jejunum by a longitudinal pancre-
atojejunostomy in addition to pancreatic head excision, leaving
behind a cuff of pancreas on the duodenal wall (Bachmann 2010).
Several variations of DPPHR, such as the Hamburg procedure
and the Berne procedure, have been reported (Bachmann 2010).
Complications related to PD and DPPHR include pancreatic fis-
tula, bleeding requiring blood transfusion, perforation, bile leak,
or anastomotic leak requiring re-operation, and medical compli-
cations such as pneumonia (Buchler 1995; Izbicki 1995).
How the intervention might work
The main purpose of surgical excision is removal of the head of
the pancreas to decompress the obstructed ducts (Braganza 2011).
Since one of the theories of the pathogenesis of the pain of pan-
creatitis is pancreatic duct hypertension caused by obstruction of
the pancreatic duct, relief of this obstruction can lead to relief of
symptoms. PD is a more extensive procedure (as there is a neces-
sity for gastroenteric and biliary enteric anastomoses) and in the
past it was generally considered the standard pancreatic resection.
It is performed on the assumption that a significant proportion
of people with chronic pancreatitis have duodenal and bile duct
stenosis (Bachmann 2010). Surgery may also be performed if it is
not possible to rule out pancreatic cancer in people with symp-
toms suggestive of chronic pancreatitis (Bachmann 2010).
Why it is important to do this review
There is currently no consensus on the surgical management of
chronic pancreatitis (Braganza 2011). This review provides the
best level of evidence on the comparative benefits and harms of
DPPHR versus PD in people with chronic pancreatitis for whom
pancreatic resection is considered the main treatment option, and
so allow such patients and the surgeons involved in their care to
make informed decisions.
O B J E C T I V E S
To assess the benefits and harms of duodenum-preserving pan-
creatic head resection versus pancreaticoduodenectomy in people
with chronic pancreatitis for whom pancreatic resection is consid-
ered the main treatment option.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) only. We in-
cluded studies reported in full text, and planned to include studies
published as an abstract only, and unpublished data.
Types of participants
We included adults with chronic pancreatitis undergoing surgical
management for chronic pancreatitis. We excluded people under-
going distal pancreatectomy or drainage procedures without any
pancreatic head resection, such as Puestow’s procedure.
Types of interventions
We included trials comparing DPPHRs (Beger procedure, Frey
procedure, or other variations of DPPHR) and PD (PPPD or
Whipple procedure). We excluded trials comparing different types
of DPPHR (Beger procedure with Frey procedure) or trials com-
paring different types of pancreatic head resection (PPPD with
Whipple procedure).
Types of outcome measures
Primary outcomes
1. All-cause mortality.
i) Short-term mortality (in-hospital mortality or
mortality within three months).
ii) Long-term mortality (maximal follow-up).
2. Treatment-related serious adverse events (within three
months). We accepted the following definitions of serious
adverse events.
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i) Clavien-Dindo classification (Clavien 2009; Dindo
2004): Grade III or greater.
ii) International Conference on Harmonisation - Good
Clinical Practice (ICH-GCP) guideline (ICH-GCP 1996):
serious adverse events defined as any untoward medical
occurrence that resulted in death, was life-threatening, required
hospitalisation or prolongation of existing hospitalisation, or
resulted in persistent or significant disability/incapacity.
iii) Individual complications such as anastomotic leak
requiring re-operation that can clearly be classified as Grade III
or greater with the Clavien-Dindo classification (Clavien 2009;
Dindo 2004), or as a serious adverse event with the ICH-GCP
classification.
iv) Clinically significant pancreatic fistulas (Type B or
Type C International Study Group on Pancreatic Fistula
Definition (ISGPF)) (Bassi 2005).
3. Health-related quality of life following surgery (using any
validated scale such as EQ5D or 36-item Short Form (SF-36))
(EuroQol 2014; Ware 2014). EQ5D assesses the quality of life
under five domains, namely mobility, self care, usual activities,
pain or discomfort, and anxiety or depression (EuroQol 2014).
SF-36 assesses the quality of life under eight sections, namely
vitality, physical functioning, bodily pain, general health
perceptions, physical role functioning, emotional role
functioning, social role functioning, and mental health (Ware
2014).
i) Short-term (four weeks to three months).
ii) Medium-term (three months to five years).
iii) Long-term (more than five years).
Secondary outcomes
1. Treatment-related adverse events (within three months),
such as wound infection or chest infection requiring antibiotic
treatment. We accepted all adverse events reported by the study
author irrespective of the severity of the adverse event.
2. Measures of earlier postoperative recovery.
i) Length of hospital stay (including the index admission
(admission during which the surgery was performed) for
pancreatic head resection and any surgical complication-related
re-admissions).
ii) Time to return to normal activity (return to pre-
operative mobility without any additional carer support or as
defined by authors).
iii) Time to return to work (in people who were employed
previously).
3. Proportion of people in employment at maximal follow-up.
4. Pain scores using a visual analogue scale.
i) Short-term (four weeks to three months).
ii) Medium-term (three months to five years).
iii) Long-term (more than five years).
5. Measures of endocrine and exocrine insufficiency at
maximal follow-up.
i) Diabetes mellitus (incidence proportion).
ii) Symptoms related to exocrine insufficiency
(prevalence proportion).
We based the choice of the above clinical outcomes on the necessity
to assess whether DPPHR is safe and beneficial in terms of earlier
postoperative recovery allowing earlier discharge from hospital,
return to normal activity, and return to work, and improvement
in health-related quality of life.
Reporting of the outcomes listed here will not be an inclusion
criterion for the review.
Search methods for identification of studies
Electronic searches
We conducted a literature search to identify all published and un-
published RCTs. The literature search identified potential studies
in all languages. We translated the non-English language papers
and assess them fully for potential inclusion in the review as nec-
essary.
We searched the following electronic databases for identifying po-
tential studies:
1. Cochrane Central Register of Controlled Trials
(CENTRAL) (Appendix 2);
2. MEDLINE (1966 to June 2015) (Appendix 3);
3. EMBASE (1988 to June 2015) (Appendix 4); and
4. Science Citation Index (1982 to June 2015) (Appendix 5).
We also conducted a search of ClinicalTrials.gov (Appendix 6) and
WorldHealthOrganization - International Clinical Trials Registry
Platform (WHO ICTRP) on 22 June 2015 (Appendix 7).
Searching other resources
We checked the reference lists of all primary studies and review ar-
ticles for additional references. We contacted the authors of iden-
tified trials and ask them to identify other published and unpub-
lished studies.
We searched for errata or retractions fromeligible trials on PubMed
on 18 July 2015.
Data collection and analysis
Selection of studies
Three review authors (KG, CL, and CH) independently screened
the titles and abstracts of all the potential studies that we identi-
fied as a result of the search and coded them as ’retrieve’ (eligible
or potentially eligible/unclear) or ’do not retrieve’. We retrieved
the full-text study reports and three review authors (KG, CL, and
CH) independently screened the full text, identified studies for
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inclusion, and identified and recorded reasons for exclusion of the
ineligible studies. We resolved any disagreement through discus-
sion. We identified and excluded duplicate references and collated
multiple reports of the same study so that each study rather than
each report was the unit of interest in the review. We recorded the
selection process in sufficient detail to complete a PRISMA flow
diagram and Characteristics of excluded studies table.
Data extraction and management
We used a standard data collection form for study characteristics
and outcome data, which was piloted on at least one study in the
review. Two review authors (KG and CL) extracted study char-
acteristics from the included studies. We planned to extract the
following study characteristics:
1. methods: study design, total duration of study and run-in,
number of study centres and location, study setting,
withdrawals, date of study;
2. participants: number, mean age, age range, gender,
American Society of Anesthesiologists (ASA) status (ASA 2015),
inclusion criteria, exclusion criteria;
3. interventions: intervention, comparison, concomitant
interventions;
4. outcomes: primary and secondary outcomes specified and
collected, time points reported;
5. notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (KG and CL) independently extracted out-
come data from the included studies. If outcomes were reported at
multiple time points, for example, long-term health-related qual-
ity of life was reported at seven years and 15 years, we chose the
later time point (i.e. 15 years) for data extraction. For time-to-
event outcomes, we extracted data to calculate the natural loga-
rithm of the hazard ratio (HR) and its standard error using the
methods suggested by Parmar et al. (Parmar 1998).
We included all randomised participants for medium- and long-
term outcomes (e.g. mortality or quality of life) and this was not
conditional upon the short-term outcomes (e.g. being alive at
three months or having a low or high quality of life index at three
months), and we included all participants for medium- and long-
term outcomes.
We planned to note in the Characteristics of included studies table
if outcome data were reported in an unusable way. We resolve
disagreements by discussions and arriving at a consensus. One
review author (KG) copied across the data from the data collection
form into ReviewManager 5 (RevMan 2014).We double checked
that the datawere entered correctly by comparing the study reports
with how the data were presented in the systematic review.
Assessment of risk of bias in included studies
Two review authors (KG and CL) independently assessed the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by involving a
third assessor (BRD). We assessed the risk of bias according to the
following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We graded each potential source of bias as high, low, or unclear and
provide a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We have summarised
the ’Risk of bias’ judgements across different studies for each of the
domains listed. We acknowledge that blinding of personnel will
be impossible but blinding of participants and outcome assessors
was possible. We considered blinding separately for different key
outcomes where necessary. For example, for unblinded outcome
assessment, the risk of bias for all-cause mortality may be very
different than for a participant-reported health-related quality of
life scale, since lack of blinding is unlikely to result in bias in
all-cause mortality, while lack of blinding is likely to introduce a
significant bias in quality of life. Where information on risk of
bias related to unpublished data or correspondence with a trialist,
we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias of the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and reported any deviations from it in the ’Differences between
protocol and review’ section of the systematic review (Gurusamy
2015).
Measures of treatment effect
We planned to analyse dichotomous data (short-term mortality,
proportion of participants with adverse and serious adverse events,
clinically significant pancreatic fistulas, proportion of people in
employment, diabetes mellitus, and symptoms related to pancre-
atic insufficiency) as a risk ratio (RR) with 95% confidence inter-
val (CI). We planned to analyse continuous data as a mean dif-
ference (MD) with 95% CI when the outcome was reported or
converted to the same units in all the trials (e.g. hospital stay, time
to return to normal activity, time to return to work, pain scores
using a visual analogue scale) or as a standardised mean difference
(SMD) with 95% CI when different scales were used for measur-
ing the outcome (e.g. quality of life). We have ensured that higher
scores for continuous outcomes have the same meaning for the
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particular outcome, explained the direction to the reader, and re-
ported where the directions were reversed if this was necessary. We
calculated the rate ratio (RAR) with 95% CI for outcomes such
as adverse events and serious adverse events, where it was possible
for the same person to develop more than one adverse event (or
serious adverse event). If the study authors had calculated the RaR
of adverse events (or serious adverse events) in the intervention
versus the control group based on Poisson regression, we planned
to obtain the RaR by the Poisson regression method in preference
to the RaR calculated based on the number of adverse events (or
serious adverse events) during a certain period. We planned to
calculate the HR with 95% CI for time-to-event outcomes such
as time to first adverse event (or serious adverse event) and long-
term survival.
We undertook meta-analyses since the treatments, participants,
and the underlying clinical question were similar enough for pool-
ing to make sense.
A common way in which trialists indicate that they have skewed
data is by reporting medians and interquartile ranges. When we
encountered this we noted that the data were skewed and consider
the implications of this.
Where multiple trial arms were reported in a single trial, we
planned to include only the relevant arms. If two comparisons (e.g.
Beger procedure versus PPPD and Frey procedure versus PPPD)
had to be entered into the samemeta-analysis, we planned to halve
the control group to avoid double counting. The alternative way
of including such trials with multiple arms is to pool the results
of the Beger procedure and Frey procedure and compare this with
PPPD. We planned to perform a sensitivity analysis to determine
if the results of the two methods of dealing with multi-arm trials
led to different conclusions.
Unit of analysis issues
The unit of analysis was the individual person undergoing pancre-
atic head resections for chronic pancreatitis. We did not anticipate
any cluster-randomised trials for this comparison but if we had
identified cluster-randomised trials, we planned to obtain the ef-
fect estimate adjusted for the clustering effect. If this was not avail-
able, we planned to perform a sensitivity analysis by excluding the
trial from the meta-analysis, as the variance of the effect estimate
unadjusted for the cluster effect is less than the actual variance
that is adjusted for the cluster effect, giving inappropriately more
weight to the cluster-RCT in the meta-analysis.
Dealing with missing data
We attempted to contact the investigators or study sponsors in or-
der to verify key study characteristics and obtain missing numeri-
cal outcome data where possible (e.g. when data were not reported
completely or when a study was identified as an abstract only). If
we were unable to obtain the information from the investigators
or study sponsors, we imputed the mean from the median (i.e.
consider the median as the mean) and the standard deviation from
the standard error or P values according to the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), when
the data did not appear to be skewed, but we assessed the impact
of including such studies as indicated in a sensitivity analysis. If
we were unable to calculate the standard deviation from the stan-
dard error or P values, we imputed the standard deviation as the
highest standard deviation in the remaining trials included in the
outcome, fully aware that this method of imputation will decrease
the weight of the studies in the meta-analysis of MD and shift the
effect towards no effect for the SMD.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. If we had identified substantial heterogeneity, as
per the Cochrane Handbook for Systematic Reviews of Interventions
(greater than 50% to 60%), we planned to explore it by pre-spec-
ified subgroup analysis. We also assessed heterogeneity by evalu-
ating whether there was good overlap of CIs.
Assessment of reporting biases
We attempted to contact study authors and ask them to provide
missing outcome data. Where this was not possible, and the miss-
ing data were thought to introduce serious bias, we explored the
impact of including such studies in the overall assessment of results
by a sensitivity analysis.
If wewere able to poolmore than10 trials, we planned to create and
examine a funnel plot to explore possible publication biases. We
planned to use Egger’s test to determine the statistical significance
of the reporting bias (Egger 1997). We planned to consider a P
value of less than 0.05 to be statistically significant reporting bias.
Data synthesis
We performed the analysis using Review Manager 5 (RevMan
2014). We used the Mantel-Haenszel method for dichotomous
data, the inverse variance method for continuous data, and the
generic inverse variance method for count and time-to-event data.
We used both the fixed-effect model (Demets 1987) and the ran-
dom-effects model (DerSimonian 1986) for the analysis. In case
of discrepancy between the two models, we reported both results;
otherwise, we reported only the results from the fixed-effectmodel.
’Summary of findings’ table
Wecreated two ’Summary of findings’ table using all the outcomes.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of the body of evidence as it relates to the stud-
ies that contribute data to the meta-analyses for the pre-specified
outcomes. We have used the methods and recommendations de-
scribed in Chapter 8.5 and Chapter 12 of the Cochrane Handbook
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for Systematic Reviews of Interventions (Higgins 2011), and using
GRADEpro software. We justified all decisions to downgrade or
upgrade the quality of studies using footnotes and we made com-
ments to aid the reader’s understanding of the review where nec-
essary. We considered whether there was any additional outcome
information that could not be incorporated into the meta-analy-
ses, and planned to note this in the comments and state whether it
supports or contradicts the information from the meta-analyses.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses:
1. people at different anaesthetic risks (ASA I or II (a healthy
person or mild systemic disease) versus ASA III or more (a
person with severe systemic disease or worse);
2. different procedures (e.g. Beger procedure versus Frey
procedure);
3. person with and without obstructive jaundice.
We planned to use all of the primary outcomes in subgroup anal-
ysis.
We planned to use the formal Chi2 test for subgroup differences
to test for subgroup interactions.
Sensitivity analysis
We planned to perform the following sensitivity analyses defined
a priori to assess the robustness of our conclusions:
1. excluding trials at unclear or high risk of bias (one of more
of the ’Risk of bias’ domains (other than blinding of the surgeon)
classified as unclear or high);
2. excluding trials in which either the mean or standard
deviation, or both, were imputed;
3. excluding cluster-RCTs in which the adjusted effect
estimates were not reported;
4. exploring different methods of dealing with multi-arm trials
(see Measures of treatment effect).
Reaching conclusions
We have based our conclusions only on the findings of the quan-
titative or narrative synthesis of included studies in this review.
We have avoided making recommendations for practice and our
implications for research and have given the reader a clear sense of
where the focus of any future research in the area should be and
what the remaining uncertainties are.
R E S U L T S
Description of studies
Results of the search
We identified 755 references through electronic searches of CEN-
TRAL (50 references), MEDLINE (OvidSP) (250 references),
EMBASE (OvidSP) (246 references), Science Citation Index ex-
panded (198 references), ClinicalTrials.gov (nine references), and
WHO ICTRP (two references). After removing duplicate refer-
ences, there were 544 references. We excluded 529 clearly irrele-
vant references through reading titles and abstracts. We retrieved
15 references for further assessment in detail, from the full publi-
cation. We excluded four references because of the reasons stated
in the Characteristics of excluded studies table (Buchler 1996;
Buchler 2008; Friess 1996; Riediger 2007). One reference is an
ongoing trial with no interim report (Diener 2010). We could not
obtain the full text of one reference (Morr 1991). Based on the
title and the author list, it appears that this is a preliminary report
of an included trial (Klempa 1995). In total, nine references de-
scribing five trials fulfilled the inclusion criteria (Characteristics of
included studies) (Buchler 1995; Farkas 2006; Izbicki 1998; Keck
2012; Klempa 1995). Figure 1 shows the study flow diagram.
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Figure 1. Study flow diagram.
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Included studies
The review included five RCTs (Buchler 1995; Farkas 2006;
Izbicki 1998; Keck 2012; Klempa 1995). All the five trials were
two-armed trials that included symptomatic participants with
chronic pancreatitis involving the head of pancreas. The trials did
not report the ASA status of the participants. All the trials were
single-centre trials. All the trials included people with and with-
out obstructive jaundice and people with and without duodenal
stenosis but did not report data separately for those with and
without jaundice and those with and without duodenal stenosis.
The five trials randomised 292 participants (Buchler 1995; Farkas
2006; Izbicki 1998; Keck 2012; Klempa 1995). After exclusion of
23 participants in four trials (Buchler 1995; Farkas 2006; Izbicki
1998; Keck 2012) (one trial did not provide information on the
number of participants randomised but simply stated the number
of participants included in the trial (Klempa 1995), 269 partic-
ipants were randomised to DPPHR (135 participants) and PD
(134 participants). The surgical procedures compared in the five
trials were:
1. Buchler 1995: Beger procedure versus Whipple procedure;
2. Farkas 2006: wide local excision of head of pancreas versus
PPPD;
3. Izbicki 1998: Frey procedure versus PPPD;
4. Keck 2012: Beger or Frey procedure versus PPPD;
5. Klempa 1995: Beger procedure versus Whipple procedure.
The participants were followed up for various periods of time rang-
ing fromone to 15 years. Four studies reportedmean follow-up pe-
riods, whichwere 14 years (Buchler 1995), one year (Farkas 2006),
15 years (Izbicki 1998), and 3.5 years (Keck 2012). One study
did not report the mean follow-up period but reported the range
of follow-up, which was between 3 and 5.5 years (Klempa 1995).
The long-term reports were published separately from short-term
reports for the two studies with long follow-up (Buchler 1995;
Izbicki 1998). The Characteristics of included studies table lists
the outcomes reported in individual trials.
Excluded studies
None of the excluded studies were RCTs (Buchler 1996; Buchler
2008; Friess 1996; Riediger 2007).
Risk of bias in included studies
None of the included trials were at low risk of bias. Figure 2 and
Figure 3 summarises the risk of bias in the individual domains.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Only one trial reported the allocation sequence generation and
allocation concealment adequately and was at low risk of selection
bias (Izbicki 1998). The remaining trials did not report the allo-
cation sequence generation (Keck 2012), allocation concealment
(Klempa 1995), or both (Buchler 1995; Farkas 2006), and hence
are at unclear risk of selection bias.
Blinding
It is not possible to blind the surgeon performing the surgical
procedure. However, it is possible to blind the participants and
outcome assessors and surgeons who make clinical decisions after
the surgery. None of the trials reported blinding of the participants
or outcome assessors. Hence, all the trials were at unclear risk of
performance bias andunclear risk of detectionbias for all outcomes
other than mortality. All-cause mortality was reported. Hence, it
is unlikely that the lack of blinding introduced bias in assessment
of mortality.
Incomplete outcome data
Four trials reported post-randomisation drop-outs due to various
reasons including pancreatic cancer, failure to undergo the treat-
ment to which they were randomised, cross-over to the other pro-
cedure because of technical requirements, participants did not re-
quire pancreatic head resection, and loss to follow-up (Buchler
1995; Farkas 2006; Izbicki 1998; Keck 2012). Of these, only one
trial presented attrition bias in terms of follow-up (Keck 2012).
We considered one trial that did not report the patient flow clearly
at unclear risk of attrition bias (Klempa 1995).
Selective reporting
All the trials reported the clinical outcomes that are likely to be
measured in such clinical trials and we considered them at low risk
of selective reporting.
Other potential sources of bias
None of the trials reported the source of funding. However, it is
unlikely that the source of funding would have any bias in this
comparison.
Four trials reported post-randomisation drop-outs due to various
reasons including pancreatic cancer, failure to undergo the treat-
ment to which they were randomised, cross-over to the other pro-
cedure because of technical requirements, participants did not re-
quire pancreatic head resection, and loss to follow-up (Buchler
1995; Farkas 2006; Izbicki 1998; Keck 2012). All of these reasons
have the potential to introduce bias in the effect estimate. For
example, the tumour might have been breached in participants
undergoing DPPHR and found to have pancreatic carcinoma in
the frozen section or paraffin-fixed biopsy while it would not have
been breached in participants undergoing PD. This might have
influenced long-term survival. So these trials were at high risk of
other bias. We considered one trial that did not report the patient
flow clearly at unclear risk of attrition bias (Klempa 1995).
Effects of interventions
See:Summaryof findings for themain comparisonDuodenum-
preserving pancreatic resection versus pancreaticoduodenectomy
for chronic pancreatitis (primary outcomes); Summary of
findings 2 Duodenum-preserving pancreatic resection versus
pancreaticoduodenectomy for chronic pancreatitis (secondary
outcomes)
Summary of findings for the main comparison and Summary of
findings 2 summarise the effects of interventions.None of the trials
reported the following outcomes: short-term quality of life (four
weeks to three months), clinically significant pancreatic fistulas,
serious adverse events, time to return to normal activity, time to
return to work, and pain scores using a visual analogue scale.
Short-term mortality (in-hospital or mortality within
three months)
All the five trials reported short-term mortality (Buchler 1995;
Farkas 2006; Izbicki 1998; Keck 2012; Klempa 1995). There were
two deaths in the DPPHR group (2/135 (1.5%) participants)
compared to no deaths in the PD group. There was no statistically
significant difference between the two groups (RR 2.89, 95% CI
0.31 to 26.87; 269 participants; 5 studies; I2 = 0%) (Analysis 1.1).
Using a random-effects model did not alter the results.
Long-term mortality (maximal follow-up)
We estimated the HRs using the methods suggested by Parmar
et al. (Parmar 1998). Four trials reported long-term mortality
(Buchler 1995; Izbicki 1998; Keck 2012; Klempa 1995). The fol-
low-up period ranged between three and 15 years. Around 70%
to 95% of participants were alive at five years in the various tri-
als. Long-term mortality was statistically significantly lower in the
DPPHR group than the PD group using a fixed-effect model (HR
0.71, 95%CI 0.51 to 0.99; 229 participants; 4 studies; I2 = 74%).
The CI of one trial (Keck 2012) did not overlap those of two other
trials (Buchler 1995; Izbicki 1998) and had only a partial overlap
with those of the fourth trial (Klempa 1995). This trial reported a
significantly lower long-termmortality in theDPPHR group than
PD group and the magnitude of the effect was greater than in the
remaining trials. There was no statistically significant difference in
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the long-termmortality between the groups on using the random-
effects model (HR 0.65, 95% CI 0.31 to 1.34; 229 participants;
4 studies; I2 = 74%) (Analysis 1.2).
Treatment-related serious adverse events
None of the included trials reported treatment-related serious ad-
verse events.
Health-related quality of life (short term: four weeks
to three months)
None of the included trials reported short-term health-related
quality of life.
Health-related quality of life (medium term: three
months to five years)
Two trials reported medium-term health-related quality of life
(Izbicki 1998; Keck 2012). Both trials used EORTC QLQ-C30
(EORTC 2015). Global health value was extracted since this rep-
resents the overall quality of life of the participants. This was a
scale of 0 to 100 with higher values indicating a better health-re-
lated quality of life. The trials reported the median scores (Izbicki
1998; Keck 2012). One trial did not report the statistical signif-
icance of the comparison (Izbicki 1998). In the other trial, there
was no statistically significant difference in medium-term health-
related quality of life between the two groups (P value = 0.66). We
did not perform a meta-analysis because of insufficient data but
provided only a narrative summary of the results (Analysis 1.3).
Health-related quality of life (long term: more than
five years)
Two trials reported long-term health-related quality of life (
Buchler 1995; Izbicki 1998). Both trials used EORTCQLQ-C30
(EORTC 2015). We extracted global health value since this rep-
resents the overall quality of life of the participants. This was a
scale of 0 to 100 with higher values indicating a better health-
related quality of life. Both the trials reported the mean and stan-
dard deviation. There was no statistically significant difference in
the long-term term health-related quality of life between the two
groups (MD 8.45, 95% CI -0.27 to 17.18; 101 participants; 2
studies; I2 = 0%) (Analysis 1.4). Using a random-effects model
did not alter the results.
Treatment-related adverse events
Four trials reported the proportion of people with adverse events in
the immediate post-operative period (Buchler 1995; Farkas 2006;
Izbicki 1998; Keck 2012). The proportion of participants with
adverse events in theDPPHR group (23/113 (adjusted proportion
20%) participants) was statistically significantly fewer in the PD
group (41/113 (36.3%) participants) (RR 0.57, 95% CI 0.37 to
0.88; 226 participants; 4 studies; I2 = 64%) when we used a fixed-
effectmodel. This appears to bemainly due to one trial that had no
adverse events in the DPPHR group (Farkas 2006). There was no
statistically significant difference in the treatment-related adverse
events between the groups on using a random-effects model (RR
0.55, 95% CI 0.22 to 1.35; 226 participants; 4 studies; I2 = 64%)
(Analysis 1.5). One trial reported the number of adverse events.
There was no statistically significant difference in the number of
adverse events between the two groups (DPPHR: 12/22 partici-
pants (54.3 events per 100 participants) versus PD: 12/21 partici-
pants (57.1 events per 100 participants) (RaR 0.95, 95% CI 0.43
to 2.12; 43 participants; 1 studies) (Analysis 1.6). Since this was
the only study that reported the number of adverse events, issues
of heterogeneity and fixed-effect versus random-effects model did
not arise.
Length of hospital stay
Four trials reported the length of hospital stay (Buchler 1995;
Farkas 2006; Keck 2012; Klempa 1995). Two trials reported the
median length of hospital stay (Buchler 1995; Keck 2012). Of
these, one trial provided the P value fromwhich we could calculate
the standard deviation (Keck 2012), while the other trial did not
provide any measure from which we could calculate the standard
deviation (Buchler 1995). Two trials reported the mean length of
hospital stay (Farkas 2006; Klempa 1995). Of these, one trial re-
ported the standard deviation (Farkas 2006). We did not perform
ameta-analysis because of insufficient information. We have tabu-
lated the results of length of hospital stay reported in these trials in
Analysis 1.7. Two trials reported statistically significant differences
in the mean length of hospital stay (about five days fewer hospital
stay in the DPPHR group compared to the PD group) (Farkas
2006; Klempa 1995), while the two trials that reported median
length of hospital stay reported one day fewer hospital stay in the
DPPHR group compared to the PD group (Buchler 1995; Keck
2012). There was no statistically significant difference in one trial
(Keck 2012), while the other trial did not report the statistical
significance (Buchler 1995). Thus, the hospital stay was one to
five days lower in the DPPHR group compared to the PD group,
although this was statistically significant in two trials only (Farkas
2006; Klempa 1995). The overall impression was that there was a
decrease in the length of hospital in the DPPHR group compared
to the PD group.
Proportion of people in employment at maximal
follow-up
Four trials reported the proportion of people in employment
(Buchler 1995; Izbicki 1998; Keck 2012; Klempa 1995). The fol-
low-up period varied between three and 15 years. The proportion
of people employed was statistically significantly higher with the
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DPPHR group (65/98 (adjusted proportion, i.e. absolute effect
obtained bymeta-analysis 69.4%)participants) than the PDgroup
(41/91 (45.1%) participants) using a fixed-effect model (RR 1.52,
95%CI 1.18 to 1.97; 189 participants; 4 studies; I2 = 43%). There
was no statistically significant difference in the proportion of peo-
ple in employment between the groups on using the random-ef-
fects model (RR 1.54, 95% CI 1.00 to 2.37; 189 participants; 4
studies; I2 = 43%) (Analysis 1.8).
Pain scores
None of the included trials reported pain scores.
Diabetes mellitus
All five trials reported new-onset diabetes mellitus (Buchler 1995;
Farkas 2006; Izbicki 1998; Keck 2012; Klempa 1995). The fol-
low-up period varied between one and 15 years). There was no
statistically significant difference in the proportion of people who
developed diabetes mellitus between the two groups (DPPHR:
25/135 (adjusted proportion 18.6%) participants versus PD: 32/
134 (23.9%) participants) (Analysis 1.9). Using the random-ef-
fects model did not alter the results.
Measures of exocrine insufficiency
Four trials reported long-term mortality (Buchler 1995; Izbicki
1998; Keck 2012; Klempa 1995). The follow-up period varied
between three and 15 years. There was no statistically significant
difference in the proportion of people who developed diabetes
mellitus between the two groups (DPPHR: 62/98 (adjusted pro-
portion 62.0%) participants versus PD: 68/91 (74.7%) partici-
pants) (Analysis 1.10). Using the random-effects model did not
alter the results.
Subgroup analysis
None of the trials reported separate data for people with different
ASA status and for people with and without jaundice. Therefore,
we did not perform these subgroup analyses. With regards to the
different types of interventions and control, the test for subgroup
differences was not statistically significant for short-term mortal-
ity, long-termmortality, and quality of life (greater than five years)
(Analysis 2.1; Analysis 2.2; Analysis 2.4). However, the treatment
effects appeared to be different between the subgroups of Beger
procedure versus classical Whipple and Frey procedure versus py-
lorus-preservingpancreatoduodenectomy, although therewas only
one trial comparing Frey procedure versus pylorus-preserving pan-
creatoduodenectomy and there was no statistically significant dif-
ference for the test for subgroup differences.We could not perform
the test for subgroup differences for quality of life (three months
to one year) since a narrative summary was performed for this out-
come and because there was only one subgroup for this outcome.
Sensitivity analysis
All the trials were at unclear or high risk of bias. Therefore, we
could not perform a sensitivity analysis of excluding trials at un-
clear or high risk of bias. We did not perform a sensitivity analysis
excluding trials in which either mean or standard deviation was
imputed since three of the four trials imputed either the mean
or standard deviation in the only outcome in which the sensitiv-
ity analysis was relevant (length of hospital stay) (Buchler 1995;
Keck 2012; Klempa 1995). Instead, we assessed whether the in-
terpretation would have changed by using a narrative summary
as mentioned earlier. There were no cluster RCTs; therefore, we
could not perform a sensitivity analysis excluding cluster RCTs
that did not report adjusted results. All the trials were two-armed
trials; therefore, we could not perform a sensitivity analysis using
different methods of dealing with multi-arm trials.
Reporting bias
We did not explore reporting bias using a funnel plot since there
were fewer than 10 trials included in this review.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Patient or population: people requiring surgery for chronic pancreatitis
Setting: surgical unit
Intervention: duodenum-preserving pancreatic resection
Comparison: pancreaticoduodenectomy
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with pancreatico-
duodenectomy
Risk with duodenum-
preserving pancreatic
resection
Adverse events (propor-
tion)
363 per 1000 200 per 1000
(80 to 490)
RR 0.55
(0.22 to 1.35)
226
(4 RCTs)
⊕©©©
Very low123
-
Adverse events (number
of adverse events)
571 per 1000 543 per 1000
(246 to 1211)
Rate ratio 0.95
(0.43 to 2.12)
43
(1 RCT)
⊕©©©
Very low12
-
Length of hospital stay The mean length of hos-
pital stay was 14 days
The mean or median
length of hospital stay
in the intervention group
was 1 to 5 days fewer
- 208
(4 RCTs)
⊕⊕©©
Low1
2 trials that reportedmean
length of hospital stay re-
ported statistically signifi-
cant fewer hospital stay in
intervention group (about
5 days fewer) (Farkas
2006; Klempa 1995),
while 2 trials that reported
the median length of hos-
pital stay reported 1 day
fewer hospital stay in in-
tervention group, which
was not statistically sig-
nificant in 1 trial (Keck
2012), while the other
trial did not report statisti-
cal significance (Buchler
1995)1
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Employed 451 per 1000 694 per 1000
(451 to 1000)
RR 1.54
(1.00 to 2.37)
189
(4 RCTs)
⊕⊕©©
Low1
-
New-onset diabetes 239 per 1000 186 per 1000
(119 to 291)
RR 0.78
(0.50 to 1.22)
269
(5 RCTs)
⊕©©©
Very low12
-
Pancreatic exocrine in-
sufficiency
747 per 1000 620 per 1000
(508 to 762)
RR 0.83
(0.68 to 1.02)
189
(4 RCTs)
⊕©©©
Very low1,2,4
-
None of the trials reported the following outcomes: quality of life (4 weeks to 3 months), clinically significant pancreatic fistulas, serious adverse events, time to return to normal activity, time
to return to work, and pain scores using a visual analogue scale
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group (mean control group proportion for all outcomes except short-
term mortality where an assumed risk of 1% was used as there was no short-term mortality in the control group in the trials included in this review) and the relative effect of the intervention
(and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 The trial(s) was/were of unclear or high risk of bias.
2 The confidence intervals were wide and the sample size was small.
3 The I2 value was high.
4 The I2 value was high and there was lack of overlap of confidence intervals.
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D I S C U S S I O N
Summary of main results
We identified five trials of 269 participants with chronic pancreati-
tis requiring surgery who received DPPHR (135 participants) or
PD (134 participants) (Buchler 1995; Farkas 2006; Izbicki 1998;
Keck 2012; Klempa 1995). None of the trials reported short-term
quality of life, clinically significant pancreatic fistulas, serious ad-
verse events, time to return to normal activity, time to return to
work, and pain scores using a visual analogue scale. There were
no statistically significant differences in short-term or long-term
mortality,medium-term or long-termquality of life, proportion of
people with adverse events, number of people with adverse events,
proportion of people employed, incidence proportion of diabetes
mellitus, and prevalence proportion of pancreatic exocrine insuf-
ficiency. The length of hospital stay appeared to be lower in the
DPPHR compared to PD and ranged between a reduction of one
and five days in the trials. The reason for the reduction in the
length of hospital day could not be explained from the informa-
tion available in this review.
Overall completeness and applicability of
evidence
All participants included in the trials in this review were people
with symptomatic chronic pancreatitis who required surgery for
their symptoms and were fit to undergo major surgery. Therefore,
this review is applicable only for people with symptomatic chronic
pancreatitis who are fit to undergo major surgery. All the trials in-
cluded people with and without obstructive jaundice and people
with and without duodenal stenosis. Therefore, this review is ap-
plicable for all people who require surgical treatment for chronic
pancreatitis involving the head of the pancreas. The commonDP-
PHR procedures such as Beger procedure and Frey procedures
were compared with PPPD and Whipple procedure. Therefore,
the results of this review are applicable to all these common proce-
dures performed in the course of surgical management of people
with chronic pancreatitis.
Quality of the evidence
The quality of evidence was either low or very low (Summary of
findings for the main comparison). The major reason for down-
grading the evidence was the risk of bias in the trials. All the trials
were at unclear or high risk of bias. One of the major sources of
bias was the lack of information on observer blinding for impor-
tant outcomes such as assessment of adverse events, decision to
discharge the participants, and assessment of quality of life. Lack
of blinding might introduce detection bias and performance bias.
Another major source of bias was ’other’ bias. A total of 23/292
(7.9%) participants were excluded from the analysis for various
reasons. Of these, the reason for post-randomisation drop-out was
due to loss to follow-up of two participants in one trial (Keck
2012). The remaining participants were excluded from analysis
because they hadpancreaticmalignancy detected intra-operatively,
underwent different procedures compared to planned procedure
due to intra-operative findings, or did not undergo pancreatic head
resection despite symptoms that were initially deemed to warrant
surgical resection. The type of procedure performed in the ex-
cluded participants could potentially affect the outcome of these
participants. If pancreatic cancer was found after the resection,
it is likely that participants undergoing the PD (either PPPD or
Whipple procedure) would have a more complete surgery in terms
of cancer clearance than people who underwent DPPHR. Since
information about pancreatic cancer is available only after the re-
section but the main question is whether to perform DPPHR or
PD, a decision that has to be made prior to the resection, a strict
intention-to-treat analysis has to be performed in future trials.
The ongoing ChroPac trial appears to overcome all these defects
in the trials included in this review as the protocol includes par-
ticipant and observer blinding and an intention-to-treat analysis
(Diener 2010). While we have classified all the trials to be free
from selective reporting bias, since the trials reported the surgery-
related mortality and complications, it should be noted that the
trials reported surgery-related complications but did not report
the importance of these complications for patient recovery. While
we acknowledge that this is the current standard practice in sur-
gical trials, the severity of the complications and their impact on
patient recovery should be reported in future trials.
Another major issue affecting the quality of evidence was the con-
sistency of evidence. While there was consistency in short-term
mortality, long-term quality of life, length of hospital stay (all tri-
als indicated a reduction in hospital stay although there was in-
consistency about the amount of reduction, i.e. the inconsistency
noted was in the magnitude of effect rather than the direction of
effect) and statistical significance, proportion of people employed
at three to 15 years, and incidence of diabetesmellitus between one
and 15 years, there was significant inconsistency in the remain-
ing outcomes. Since there is no universal definition of pancreatic
exocrine insufficiency (Lindkvist 2013), there is likely to be some
variability in the measurement of exocrine insufficiency. However,
there is no other explanation for the heterogeneity in the other
outcomes other than differences in the population (there were no
major differences in the type of people included in the trials) or in
the intervention (there is currently no evidence of any differences
in the clinical outcomes between different DPPHR procedures
(Izbicki 1995), and the ChroPac trial includes different DPPHR
procedures as intervention (Diener 2010), indicating the general
perception that the surgeons believe that there are no major differ-
ences in the clinical outcomes between different DPPHR proce-
dures). Thus, the heterogeneity observed in some of the outcomes
is largely unexplained and decreases the confidence in the results
20Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of these outcomes.
The third major issue is the precision of the outcomes. While the
major advantage of a meta-analysis is the improvement in preci-
sion, the trials included in this review reported on only 269 par-
ticipants randomised to DPPHR and PD. Only a fraction of these
participants were included in the different outcomes, particularly
for long-term outcomes. Because of this, most outcomes had im-
precise results (i.e. the CIs were wide). As a result, clinically sig-
nificant benefits or harms cannot be ruled out. The ChroPac trial
plans to include 200 participants who will be randomised on 1:1
basis to DPPHR and PD. The inclusion of this trial may improve
the precision of short-term outcomes but is unlikely to improve the
precision of long-term outcomes since this trial includes a follow-
up period of 24 months only. Although there were no statistically
significant differences in long-term mortality, long-term quality
of life, and the proportion of people at work at maximal follow-
up, there was a consistent trend favouring DPPHR for long-term
quality of life and proportion of people at work maximal follow-
up. Thus, long-term follow-up is necessary to determine the true
clinical differences between the treatments. Clearly, long-term fol-
low-up of participants in RCTs is difficult and can be a very high
resource-consuming activity. Linking trial participants to health
databases (e.g. general practitioner (GP) register), social databases
(e.g. unemployment registers), and mortality registers may over-
come this difficulty to a certain extent.
Potential biases in the review process
We have added two outcomes, namely long-term mortality and
proportion employed at maximal follow-up. These are important
clinical outcomes and addition of these clinical outcomes did not
change the conclusions of this review. However, they showed that
long-term follow-up is necessary to assess the true benefits and
harms of the treatment.
Agreements and disagreements with other
studies or reviews
There have been three previous systematic reviews of RCTs and
meta-analyses on this topic (Diener 2008; Jiang 2014; Lu 2013).
All these reviews concluded that DPPHR is superior to PD either
in the short-term or in the long-term.We are much more cautious
in our interpretation because of the quality of the evidence, in
particular, the risk of bias, inconsistency in the results, and the
imprecision in the results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Low quality evidence suggested that duodenum-preserving pan-
creatic resection may result in shorter hospital stay than pancre-
aticoduodenectomy. Based on low or very low quality evidence,
there is currently no evidence of any difference in the mortality,
adverse events, or quality of life between duodenum-preserving
pancreatic resection and pancreaticoduodenectomy. However, the
results are imprecise and further randomised controlled trials are
required on this topic.
Implications for research
Future randomised controlled trials comparing duodenum-
preserving pancreatic resection with pancreaticoduodenectomy
should report the severity of post-operative complications and
their impact on a person’s recovery. In such trials, participant and
observer blinding should be performed and the analysis should
be performed on an intention-to-treat basis to decrease bias. In
addition to the short-term benefits and harms, such as mortality,
surgery-related complications, quality of life, length of hospital
stay, return to normal activity, and return to work, future trials
should consider linkage of trial participants to health databases,
social databases, and mortality registers to obtain the long-term
benefits and harms the different treatments.
A C K N OW L E D G E M E N T S
We thank Karin Dearness, Managing Editor, Cochrane Upper
Gastrointestinal and Pancreatic Diseases (UGPD) Group, for pro-
viding administrative and logistical support for the conduct of the
current review.
We thank the copy editors and Cochrane Editorial Unit for their
comments.
21Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Buchler 1995 {published data only}
Buchler MW, Friess H, Muller MW, Wheatley AM, Beger
HG. Randomized trial of duodenum-preserving pancreatic
head resection versus pylorus-preserving Whipple in chronic
pancreatitis. American Journal of Surgery 1995;169(1):65–9.
Friess H, Muller MW, Buchler MW. Duodenum-preserving
resection of the head of the pancreas: the future. Digestive
Surgery 1994;11(3-6):318–24.
Müller MW, Friess H, Martin DJ, Hinz U, Dahmen R,
Büchler MW. Long-term follow-up of a randomized clinical
trial comparing Beger with pylorus-preserving Whipple
procedure for chronic pancreatitis. British Journal of Surgery
2008;95(3):350–6.
Farkas 2006 {published data only}
Farkas G, Leindler L, Daroczi M, Farkas G Jr.
Prospective randomised comparison of organ-preserving
pancreatic head resection with pylorus-preserving
pancreaticoduodenectomy. Langenbecks Archives of Surgery
2006;391(4):338–42.
Izbicki 1998 {published data only}
Bachmann K, Tomkoetter L, Kutup A, Erbes J, Vashist Y,
Mann O, et al. Is the Whipple procedure harmful for long-
term outcome in treatment of chronic pancreatitis? 15-years
follow-up comparing the outcome after pylorus-preserving
pancreatoduodenectomy and Frey procedure in chronic
pancreatitis. Annals of Surgery 2013;258(5):815–20.
Izbicki JR, Bloechle C, Broering DC, Knoefel WT, Kuechler
T, Broelsch CE. Extended drainage versus resection in
surgery for chronic pancreatitis: a prospective randomized
trial comparing the longitudinal pancreaticojejunostomy
combined with local pancreatic head excision with the
pylorus-preserving pancreatoduodenectomy. Annals of
Surgery 1998;228(6):771–9.
Strate T, Bachmann K, Busch P, Mann O, Schneider C,
Bruhn JP, et al. Resection vs drainage in treatment of
chronic pancreatitis: long-term results of a randomized trial.
Gastroenterology 2008;134(5):1406–11.
Keck 2012 {published data only}
Keck T, Adam U, Makowiec F, Riediger H, Wellner
U, Tittelbach-Helmrich D, et al. Short- and long-term
results of duodenum preservation versus resection for
the management of chronic pancreatitis: a prospective,
randomized study. Surgery 2012;152(3 Suppl 1):S95–s102.
Klempa 1995 {published data only}
Klempa I, Spatny M, Menzel J, Baca I, Nustede R,
Stockman F, et al. Prospective randomized study -
comparison of pancreatic function and quality-of-life after
duodenum-preserving resection of the head of the pancreas
and pancreaticoduodenectomy. Chirurg 1995;66(4):350–9.
References to studies excluded from this review
Buchler 1996 {published data only}
Buchler MW, Lubke D, Muller MW, Friess H. Comparison
between pylorus-preserving Whipple operation and
duodenum-preserving pancreatic head resection. Acta
Chirurgica Austriaca 1996;28(4):200–4.
Buchler 2008 {published data only}
Buchler MW, Warshaw AL. Resection versus drainage in
treatment of chronic pancreatitis. Gastroenterology 2008;
134(5):1605–7.
Friess 1996 {published data only}
Friess H. Which is the better operation in chronic
pancreatitis: pylorus-preserving Whipple or duodenum-
preserving pancreatic head resection?. Digestive Surgery
1996;13(2):141–9.
Riediger 2007 {published data only}
Riediger H, Adam U, Fischer E, Keck T, Pfeffer F, Hopt
UT, et al. Long-term outcome after resection for chronic
pancreatitis in 224 patients. Journal of Gastrointestinal
Surgery 2007;11(8):949–59.
References to studies awaiting assessment
Morr 1991 {published data only}
Morr H, Baca I, Schafmayer A, Klempa I. Partial
duodenopancreatectomy and duodenum-preserving
resection of the head of the pancreas in the treatment of
chronic pancreatitis: preliminary comparative clinical trial.
Langenbecks Archiv für Chirurgie 1991;Suppl:335–8.
References to ongoing studies
Diener 2010 {published data only}
Diener MK, Bruckner T, Contin P, Halloran C, Glanemann
M, Schlitt HJ, et al. Chropac-trial: duodenum-preserving
pancreatic head resection versus pancreatoduodenectomy
for chronic pancreatitis. Trial protocol of a randomised
controlled multicentre trial. Trials 2010;11:47.
Additional references
Ahmed Ali 2014
Ahmed Ali U, Jens S, Busch ORC, Keus F, van Goor
H, Gooszen HG, et al. Antioxidants for pain in chronic
pancreatitis. Cochrane Database of Systematic Reviews 2014,
Issue 8. [DOI: 10.1002/14651858.CD008945.pub2]
Ammann 1997
Ammann RW. A clinically based classification system for
alcoholic chronic pancreatitis: summary of an international
workshop on chronic pancreatitis. Pancreas 1997;14(3):
215–21.
ASA 2015
American Society of Anesthesiologists. ASA physical status
classification system, 2015. www.asahq.org/resources/
clinical-information/asa-physical-status-classification-
system (accessed on 6 February 2015).
22Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bachmann 2010
Bachmann K, Kutup A, Mann O, Yekebas E, Izbicki JR.
Surgical treatment in chronic pancreatitis timing and
type of procedure. Best Practice & Research: Clinical
Gastroenterology 2010;24(3):299–310.
Bagul 2006
Bagul A, Siriwardena AK. Evaluation of the Manchester
classification system for chronic pancreatitis. Journal of the
Pancreas 2006;7(4):390–6.
Bassi 2005
Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo
C, Izbicki J, et al. Postoperative pancreatic fistula: an
international study group (ISGPF) definition. Surgery
2005;138(1):8–13.
Bradley 2003
Bradley EL 3rd, Bem J. Nerve blocks and neuroablative
surgery for chronic pancreatitis. World Journal of Surgery
2003;27(11):1241–8.
Braganza 2011
Braganza JM, Lee SH, McCloy RF, McMahon MJ. Chronic
pancreatitis. Lancet 2011;377(9772):1184–97.
Buchler 2009
Buchler MW, Martignoni ME, Friess H, Malfertheiner
P. A proposal for a new clinical classification of chronic
pancreatitis. BMC Gastroenterology 2009;9:93.
Clavien 2009
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo
D, Schulick RD, et al. The Clavien-Dindo classification
of surgical complications: five-year experience. Annals of
Surgery 2009;250(2):187–96.
D’Haese 2014
D’Haese JG, Ceyhan GO, Demir IE, Layer P, Uhl W,
Lohr M, et al. Pancreatic enzyme replacement therapy
in patients with exocrine pancreatic insufficiency due to
chronic pancreatitis: a 1-year disease management study on
symptom control and quality of life. Pancreas 2014;43(6):
834–41.
Demets 1987
Demets DL. Methods for combining randomized clinical
trials: strengths and limitations. Statistics in Medicine 1987;
6(3):341–50.
DerSimonian 1986
DerSimonian R, Laird N. Meta-analysis in clinical trials.
Controlled Clinical Trials 1986;7(3):177–88.
Di Sebastiano 2004
Di Sebastiano P, di Mola FF, Buchler MW, Friess H.
Pathogenesis of pain in chronic pancreatitis. Digestive
Diseases 2004;22(3):267–72.
Diener 2008
Diener MK, Rahbari NN, Fischer L, Antes G, Buchler MW,
Seiler CM. Duodenum-preserving pancreatic head resection
versus pancreatoduodenectomy for surgical treatment of
chronic pancreatitis: a systematic review and meta-analysis.
Annals of Surgery 2008;247(6):950–61.
Dindo 2004
Dindo D, Demartines N, Clavien PA. Classification of
surgical complications: a new proposal with evaluation in a
cohort of 6336 patients and results of a survey. Annals of
Surgery 2004;240(2):205–13.
Dite 2001
Dite P, Stary K, Novotny I, Precechtelova M, Dolina J,
Lata J, et al. Incidence of chronic pancreatitis in the
Czech Republic. European Journal of Gastroenterology and
Hepatology 2001;13(6):749–50.
Dominguez-Munoz 2014
Dominguez-Munoz JE, Lucendo A, Carballo LF, Iglesias-
Garcia J, Tenias JM. A Spanish multicenter study to estimate
the prevalence and incidence of chronic pancreatitis and its
complications. Revista Española de Enfermedades Digestivas
2014;106(4):239–45.
Egger 1997
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-
analysis detected by a simple, graphical test. BMJ (Clinical
Research Ed.) 1997;315(7109):629–34.
EORTC 2015
EORTC Quality of Life. EORTC QLQ-C30, 2015.
groups.eortc.be/qol/eortc-qlq-c30 (accessed 18 July 2015).
EuroQol 2014
EuroQol. About EQ-5D. www.euroqol.org/about-eq-
5d.html (accessed 8 October 2014).
Fasanella 2007
Fasanella KE, Davis B, Lyons J, Chen Z, Lee KK, Slivka A,
et al. Pain in chronic pancreatitis and pancreatic cancer.
Gastroenterology Clinics of North America 2007;36(2):335-
64, ix.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
ICH-GCP 1996
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use. Code of Federal Regulation & ICH Guidelines.
Media: Parexel Barnett, 1996.
Izbicki 1995
Izbicki JR, Bloechle C, Knoefel WT, Kuechler T, Binmoeller
KF, Broelsch CE. Duodenum-preserving resection of the
head of the pancreas in chronic pancreatitis. A prospective,
randomized trial. Annals of Surgery 1995;221(4):350–8.
Jiang 2014
Jiang K, Wu K, Liao Y, Tu B. A meta-analysis of surgery
treatment of chronic pancreatitis with an inflammatory mass
in the head of pancreas: duodenum-preserving pancreatic
head resection versus pancreatoduodenectomy. Chinese
Journal of Surgery 2014;52(9):668–74.
Joergensen 2010
Joergensen M, Brusgaard K, Cruger DG, Gerdes AM,
de Muckadell OB. Incidence, prevalence, etiology, and
23Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
prognosis of first-time chronic pancreatitis in young
patients: a nationwide cohort study. Digestive Diseases and
Sciences 2010;55(10):2988–98.
Lindkvist 2013
Lindkvist B. Diagnosis and treatment of pancreatic exocrine
insufficiency. World Journal of Gastroenterology 2013;19
(42):7258–66.
Lu 2013
Lu WP, Shi Q, Zhang WZ, Cai SW, Jiang K, Dong JH. A
meta-analysis of the long-term effects of chronic pancreatitis
surgical treatments: duodenum-preserving pancreatic head
resection versus pancreatoduodenectomy. Chinese Medical
Journal 2013;126(1):147–53.
Malfertheiner 1995
Malfertheiner P, Mayer D, Buchler M, Dominguez-Munoz
JE, Schiefer B, Ditschuneit H. Treatment of pain in chronic
pancreatitis by inhibition of pancreatic secretion with
octreotide. Gut 1995;36(3):450–4.
NCBI 2014
NCBI. MeSH. NLM Controlled Vocabulary. Pancreas,
2014. www.ncbi.nlm.nih.gov/mesh/68010179 (accessed 4
July 2014).
Olesen 2011
Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor
H, Drewes AM. Pregabalin reduces pain in patients with
chronic pancreatitis in a randomized, controlled trial.
Gastroenterology 2011;141(2):536–43.
Parmar 1998
Parmar MK, Torri V, Stewart L. Extracting summary
statistics to perform meta-analyses of the published literature
for survival endpoints. Statistics in Medicine 1998;17(24):
2815–34.
Puli 2009
Puli SR, Reddy JB, Bechtold ML, Antillon MR, Brugge
WR. EUS-guided celiac plexus neurolysis for pain due to
chronic pancreatitis or pancreatic cancer pain: a meta-
analysis and systematic review. Digestive Diseases and
Sciences 2009;54(11):2330–7.
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Schneider 2007
Schneider A, Lohr JM, Singer MV. The M-ANNHEIM
classification of chronic pancreatitis: introduction of a
unifying classification system based on a review of previous
classifications of the disease. Journal of Gastroenterology
2007;42(2):101–19.
Shah 2009
Shah NS, Siriwardena AK. Variance in elective surgery for
chronic pancreatitis. Journal of the Pancreas 2009;10(1):
30–6.
Shimosegawa 2010
Shimosegawa T, Kataoka K, Kamisawa T, Miyakawa
H, Ohara H, Ito T, et al. The revised Japanese clinical
diagnostic criteria for chronic pancreatitis. Journal of
Gastroenterology 2010;45(6):584–91.
Spanier 2013
Spanier B, Bruno MJ, Dijkgraaf MG. Incidence and
mortality of acute and chronic pancreatitis in the
Netherlands: a nationwide record-linked cohort study for
the years 1995-2005. World Journal of Gastroenterology
2013;19(20):3018–26.
Ware 2014
Ware JE. SF-36® health survey update, 2014. www.sf-
36.org/tools/sf36.shtml (accessed 8 October 2014).
Yadav 2011
Yadav D, Timmons L, Benson JT, Dierkhising RA,
Chari ST. Incidence, prevalence, and survival of chronic
pancreatitis: a population-based study. American Journal of
Gastroenterology 2011;106(12):2192–9.
References to other published versions of this review
Gurusamy 2015
Gurusamy K. Duodenum-preserving pancreatic resection
versus pancreaticoduodenectomy for chronic pancreatitis.
Cochrane Database of Systematic Reviews 2015, Issue 2.
[DOI: 10.1002/14651858.CD011521]
∗ Indicates the major publication for the study
24Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Buchler 1995
Methods Randomised controlled trial
Participants Country: Germany
Number randomised: 48
Post-randomisation drop-outs: 8 (16.7%)
Revised sample size: 40
Mean age (years): 45
Women: 4 (10%)
Follow-up period (years): 14
Number of study centres: 1
Inclusion criteria
1. People were enrolled in the study when they presented with pancreatic head
enlargement defined as a diameter of > 4 cm in contrast-enhanced CT scan
2. Obstruction of the common bile or pancreatic duct or duodenum
3. Entrapment of the retroperitoneal portal vein or superior mesenteric artery
4. General condition suitable for either a DPPHR or a Whipple procedure
Interventions Participants were randomly assigned to 1 of 2 groups
Group 1: duodenum-preserving pancreatoduodenectomy (n = 20) (23 participants were
randomised)
Further details: Beger procedure
Group 2: pancreatoduodenectomy (n = 20) (25 participants were randomised)
Further details: Whipple procedure
Outcomes Mortality, post-operative complications, quality of life, length of hospital stay, proportion
of people employed, diabetes, and exocrine insufficiency
Notes Reasons for post-randomisation drop-outs: pancreatic cancer (n = 1), did not require
pancreatic head resection (n = 7)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available
Allocation concealment (selection bias) Unclear risk Comment: this information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: information on participant blinding was not
available. It is impossible to blind surgeons who perform
the procedure
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Buchler 1995 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no participants were lost to follow-up, al-
though some participants were excluded from analysis
(see other bias)
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported
Other bias High risk Comment: 1 participant had pancreatic cancer intra-op-
eratively and underwent Whipple procedure. The group
to which this participant was randomised was not stated.
7 other participants were excluded from the analysis since
they did not require pancreatic head resection. All the
participants were symptomatic. Therefore, the reason for
abandoning surgeries was not clear
Farkas 2006
Methods Randomised controlled trial
Participants Country: Hungary
Number randomised: 45.
Post-randomisation drop-outs: 5 (11.1%)
Revised sample size: 40
Mean age (years): 44
Women: 10 (25%)
Follow-up period (years): 1
Number of study centres: 1
Inclusion criteria
1. Pancreatic head enlargement, defined as a diameter of > 4 cm in a contrast-
enhanced CT scan
2. Intractable pain and obstruction of the common bile or pancreatic duct or
duodenum
Exclusion criteria
1. Myocardial infarction within the previous 6 months
2. Detection of a malignant pancreatic tumour
Interventions Participants were randomly assigned to 1 of 2 groups
Group 1: duodenum-preserving pancreatoduodenectomy (n = 20) (23 participants were
randomised)
Further details: wide local excision of head of pancreas
Group 2: pancreatoduodenectomy (n = 20) (22 participants were randomised)
Further details: PPPD
Outcomes Mortality, post-operative complications, length of hospital stay, and diabetes
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Farkas 2006 (Continued)
Notes Reasons for post-randomisation drop-outs: pancreatic carcinoma confirmed by histolog-
ical examination of a frozen section intraoperatively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available
Allocation concealment (selection bias) Unclear risk Comment: this information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information on participant blinding was not
available. It is impossible to blind surgeons who perform
the procedure
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no participants were lost to follow-up, al-
though some participants were excluded from analysis
(see other bias)
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported
Other bias High risk Comment: participants were excluded because they were
found tohave pancreatic cancer intraoperatively. This can
introduce bias since the intervention (duodenum-pre-
serving pancreatoduodenectomy) is a less invasive proce-
dure than control (pancreatoduodenectomy)
Izbicki 1998
Methods Randomised controlled trial
Participants Country: Germany
Number randomised: 64
Post-randomisation drop-outs: 3 (4.7%)
Revised sample size: 61
Mean age (years): 44
Women: 10 (16.4%)
Follow-up period (years): 15
Number of study centres: 1
Inclusion criteria
1. Inclusion criteria were an inflammatory mass in the head of the pancreas (> 35
mm in diameter)
2. Severe recurrent pain attacks (at least 1 per month requiring opiates)
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Izbicki 1998 (Continued)
3. History of pain attacks for at least 1 year
4. Co-existing complications from adjacent organs (e.g. common bile duct stenosis,
duodenal stenosis)
Exclusion criteria
1. Chronic pancreatitis without involvement of the pancreatic head
2. Small duct disease (maximal diameter of duct Wirsung = 3 mm)
3. Pseudocysts without duct pathology
4. Portal vein thrombosis
5. Myocardial infarction within 6 months
6. Detection of a malignant pancreatic tumour
7. Co-existing malignancy of other organs
Interventions Participants were randomly assigned to 1 of 2 groups
Group 1: duodenum-preserving pancreatoduodenectomy (n = 31) (32 participants were
randomised)
Further details: Frey procedure
Group 2: pancreatoduodenectomy (n = 30) (32 participants were randomised)
Further details: PPPD
Outcomes Mortality, post-operative complications, quality of life, proportion of people employed,
diabetes, and exocrine insufficiency
Notes Reasons for post-randomisation drop-outs: pancreatic carcinoma found on frozen section
biopsy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed using a list of
random digits that were made available during surgery as
coded cards sealed in envelopes”
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed using a list of
random digits that were made available during surgery as
coded cards sealed in envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information on participant blinding was not
available. It is impossible to blind surgeons who perform
the procedure
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: quality of life and pain score data were
recordedby doctoral studentswhowere unaware of group
allocation. It was not clear whether the remaining out-
comes were assessed by blinded outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no participants were lost to follow-up, al-
though some participants were excluded from analysis
(please see other bias)
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Izbicki 1998 (Continued)
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported
Other bias High risk Comment: participants were excluded because they were
found tohave pancreatic cancer intraoperatively. This can
introduce bias since the intervention (duodenum-pre-
serving pancreatoduodenectomy) is a less invasive proce-
dure than control (pancreatoduodenectomy)
Keck 2012
Methods Randomised controlled trial
Participants Country: Germany
Number randomised: 92
Post-randomisation drop-outs: 7 (7.6%)
Revised sample size: 85
Mean age (years): 42
Women: 13 (15.3%)
Follow-up period (years): 3.5
Number of study centres: 1
Inclusion criteria
1. Radiological signs of chronic pancreatitis (inflammatory head mass, calcifications,
duct abnormalities)
2. Severe recurrent pain attacks
3. Complications involving adjacent organs (e.g. biliary duodenal stenosis or
pseudocysts)
Exclusion criteria
1. Presence of complications not allowing PPPD and DPPHR. e.g. stenosis of distal
stomach, suspicion of or generalised portal hypertension
Interventions Participants were randomly assigned to 1 of 2 groups
Group 1: duodenum-preserving pancreatoduodenectomy (n = 42)
Further details: Beger or Frey procedure
Group 2: pancreatoduodenectomy (n = 43)
Further details: PPPD
Outcomes Mortality, post-operative complications, quality of life, length of hospital stay, proportion
of people employed, diabetes, and exocrine insufficiency
Notes Reasons for post-randomisation drop-outs: 2 participants in PPPD group underwent
classic Whipple procedure and 3 participants in the DPPHR group underwent PPPD;
2 participants were lost to follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
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Keck 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed before the oper-
ation via coded cards in sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information on participant blinding was not
available. It is impossible to blind surgeons who perform
the procedure
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 2 participants were lost to follow-up
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported
Other bias High risk Comment: participants were excluded because they did
not receive the planned operation. The reasons for this
were: 2 participants in the PPPD group under classic
Whipple procedure owing to severe inflammatory in-
volvement of the distal stomach and 3 participants in the
DPPHR group underwent PPPD because of suspicion
of malignancy
Klempa 1995
Methods Randomised controlled trial
Participants Country: Germany
Number randomised: 43
Post-randomisation drop-outs: not stated
Revised sample size: 43
Mean age (years): 47 years
Women: 10 (23.3%)
Follow-up period (years): range 3-5.5 years (mean not reported)
Number of study centres: 1
Inclusion criteria
1. Ongoing chronic obstructive pancreatitis for multiple (3-12) years with pain
requiring analgesia or with severe pain as judged by independent investigators in a
repeated manner (second opinion)
2. Complications such as choledochostenosis causing jaundice, duodenal stenosis
with stomach emptying disorders, compression of the duct of Wirsung in the head part
of the organ, multiple pseudoaneurysm of the pancreatic head, transverse colon
stenosis, segmental portal hypertension with compression of the superior mesenteric
vein
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Klempa 1995 (Continued)
Interventions Participants were randomly assigned to 1 of 2 groups
Group 1: duodenum-preserving pancreatoduodenectomy (n = 22)
Further details: Beger procedure
Group 2: pancreatoduodenectomy (n = 21)
Further details: Whipple procedure
Outcomes Mortality, post-operative complications, length of hospital stay, proportion of people
employed, diabetes, and exocrine insufficiency
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the patients according to the random number
list (created prior to the study) were classified into two
groups”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information on participant blinding was not
available. It is impossible to blind surgeons who perform
the procedure
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported
Other bias Unclear risk Comment: it was not clear whether participants were
excluded because of malignancy
CT: computed tomography; DPPHR: duodenum-preserving pancreatic head resection; n: number of participants; PPPD: pylorus-
preserving pancreaticoduodenectomy.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Buchler 1996 Not a randomised controlled trial
Buchler 2008 Editorial on a long-term follow-up report of an included study (Izbicki 1995)
Friess 1996 Not a randomised controlled trial
Riediger 2007 Not a randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Morr 1991
Methods Could not obtain neither an abstract nor a full-text publication
Participants Chronic pancreatitis
Interventions Duodenum-preserving pancreatic resection (further details not available) vs. pancreaticoduodenectomy (further de-
tails not available)
Outcomes This information was not available
Notes This is likely to be a preliminary report of Klempa 1995 or based on the title that states ’preliminary clinical trial’
and the author list
Characteristics of ongoing studies [ordered by study ID]
Diener 2010
Trial name or title ChroPac
Methods Multicentre randomised controlled trial (observer and participant blinded)
Participants People scheduled for primary elective surgery for chronic head pancreatitis
Interventions Duodenum-preserving pancreatic resection (Beger procedure, Frey procedure, or Berne procedure)
Outcomes Mortality, complications including pancreatic fistula, health-related quality of life, length of hospital stay,
exocrine insufficiency, and new-onset diabetes mellitus
Starting date 18 May 2009
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Diener 2010 (Continued)
Contact information Dr Christoph Seiler (Christoph.Seiler@med.uni-heidelberg.de) and Prof Marcus Buchler (
Markus.Buechler@med.uni-heidelberg.de)
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality 5 269 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [0.31, 26.87]
2 Long-term mortality 4 229 Hazard Ratio (Random, 95% CI) 0.65 [0.31, 1.34]
3 Quality of life (3 months to 5
years)
Other data No numeric data
4 Quality of life (> 5 years) 2 101 Mean Difference (IV, Fixed, 95% CI) 8.45 [-0.27, 17.18]
5 Adverse events (proportion) 4 226 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.22, 1.35]
6 Adverse events (number of
adverse events)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
7 Length of hospital stay Other data No numeric data
8 Employed 4 189 Risk Ratio (M-H, Random, 95% CI) 1.54 [1.00, 2.37]
9 New-onset diabetes 5 269 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.50, 1.22]
10 Pancreatic exocrine
insufficiency
4 189 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
Comparison 2. Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy (subgroup analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality 4 184 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [0.31, 26.87]
1.1 Beger procedure vs.
Whipple procedure
2 83 Risk Ratio (M-H, Fixed, 95% CI) 2.87 [0.12, 66.75]
1.2 Frey procedure
vs. pylorus-preserving
pancreaticoduodenectomy
1 61 Risk Ratio (M-H, Fixed, 95% CI) 2.91 [0.12, 68.66]
1.3 Wide local excision
of head of pancreas
vs. pylorus-preserving
pancreaticoduodenectomy
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Long-term mortality 3 Hazard Ratio (Random, 95% CI) 0.87 [0.60, 1.26]
2.1 Beger procedure vs.
Whipple procedure
2 Hazard Ratio (Random, 95% CI) 1.19 [0.68, 2.07]
2.2 Frey procedure
vs. pylorus-preserving
pancreaticoduodenectomy
1 Hazard Ratio (Random, 95% CI) 0.71 [0.45, 1.11]
3 Quality of life (3 months to 1
year)
Other data No numeric data
3.1 Frey procedure
vs. pylorus-preserving
pancreaticoduodenectomy
Other data No numeric data
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4 Quality of life (> 5 years) 2 101 Mean Difference (IV, Fixed, 95% CI) 8.45 [-0.27, 17.18]
4.1 Beger procedure vs.
Whipple procedure
1 40 Mean Difference (IV, Fixed, 95% CI) 6.70 [-11.19, 24.59]
4.2 Frey procedure
vs. pylorus-preserving
pancreaticoduodenectomy
1 61 Mean Difference (IV, Fixed, 95% CI) 9.0 [-0.99, 18.99]
Analysis 1.1. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 1 Short-term mortality.
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome: 1 Short-term mortality
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buchler 1995 0/20 0/20 Not estimable
Farkas 2006 0/20 0/20 Not estimable
Izbicki 1998 1/31 0/30 49.8 % 2.91 [ 0.12, 68.66 ]
Keck 2012 0/42 0/43 Not estimable
Klempa 1995 1/22 0/21 50.2 % 2.87 [ 0.12, 66.75 ]
Total (95% CI) 135 134 100.0 % 2.89 [ 0.31, 26.87 ]
Total events: 2 (Duodenum preserving), 0 (Pancreaticoduodenectomy)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours duo preserving Favours panc duodenectomy
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Analysis 1.2. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 2 Long-term mortality.
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome: 2 Long-term mortality
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomyl g [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Buchler 1995 20 20 0.216633 (0.32197) 28.0 % 1.24 [ 0.66, 2.33 ]
Izbicki 1998 31 30 -0.34813 (0.229911) 31.3 % 0.71 [ 0.45, 1.11 ]
Keck 2012 42 43 -1.6864 (0.465872) 22.8 % 0.19 [ 0.07, 0.46 ]
Klempa 1995 22 21 0 (0.616441) 17.9 % 1.00 [ 0.30, 3.35 ]
Total (95% CI) 115 114 100.0 % 0.65 [ 0.31, 1.34 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 11.65, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours duo preserving Favours panc duodenectomy
Analysis 1.3. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 3 Quality of life (3 months to 5 years).
Quality of life (3 months to 5 years)
Study Quality of life scale used
and time of measurement
Median score in duode-
num preserving pancre-
atic resection group
Me-
dian score in pancreatico-
duodenectomy group
Statistical significance
Izbicki 1998 EORTC QLQ-C30 global
health status (higher scores
indicate better quality of
life); median follow-up 24
months (range 12 months
to 36 months)
85.7 28.6 Not reported
Keck 2012 EORTC QLQ-C30 global
health status (higher scores
indicate better quality of
life); median follow-up 41
months (range 3 months to
80 months)
67 67 P = 0.66 (not significant)
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Analysis 1.4. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 4 Quality of life (> 5 years).
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome: 4 Quality of life (> 5 years)
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Buchler 1995 20 65 (22.3) 20 58.3 (34.2) 23.8 % 6.70 [ -11.19, 24.59 ]
Izbicki 1998 31 67 (19.9) 30 58 (19.9) 76.2 % 9.00 [ -0.99, 18.99 ]
Total (95% CI) 51 50 100.0 % 8.45 [ -0.27, 17.18 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours panc duodenectomy Favours duo preserving
Analysis 1.5. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 5 Adverse events (proportion).
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome: 5 Adverse events (proportion)
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomy Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Buchler 1995 3/20 4/20 22.0 % 0.75 [ 0.19, 2.93 ]
Farkas 2006 0/20 8/20 8.5 % 0.06 [ 0.00, 0.96 ]
Izbicki 1998 6/31 16/30 33.0 % 0.36 [ 0.16, 0.80 ]
Keck 2012 14/42 13/43 36.5 % 1.10 [ 0.59, 2.06 ]
Total (95% CI) 113 113 100.0 % 0.55 [ 0.22, 1.35 ]
Total events: 23 (Duodenum preserving), 41 (Pancreaticoduodenectomy)
Heterogeneity: Tau2 = 0.48; Chi2 = 8.29, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours duo preserving Favours panc duodenectomy
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Analysis 1.6. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 6 Adverse events (number of adverse events).
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome: 6 Adverse events (number of adverse events)
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomylog [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Klempa 1995 22 21 -0.05 (0.41) 0.95 [ 0.43, 2.12 ]
0.5 0.7 1 1.5 2
Favours duo preserving Favours panc duodenectomy
Analysis 1.7. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 7 Length of hospital stay.
Length of hospital stay
Study Mean or median in duo-
denum-preserving
pancreatic head resection
group (days)
Mean or
median in pancreatoduo-
denectomy group (days)
Difference in means or
median (days)
Statistical significance
Buchler 1995 13 days (median) 14 days (median) -1 days Not reported
Farkas 2006 8.5 days (mean) 13.8 days (mean) -5.3 days P < 0.05 (statistically signif-
icant)
Keck 2012 13 days (median) 14 days (median) -1 days P = 0.17 (not statistically
significant)
Klempa 1995 16.5 days (mean) 21.7 days (mean) -5.2 days P < 0.05 (statistically signif-
icant)
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Analysis 1.8. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 8 Employed.
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome: 8 Employed
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomy Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Buchler 1995 7/15 1/14 4.5 % 6.53 [ 0.92, 46.60 ]
Izbicki 1998 11/21 3/14 12.7 % 2.44 [ 0.83, 7.22 ]
Keck 2012 32/42 27/43 49.1 % 1.21 [ 0.91, 1.61 ]
Klempa 1995 15/20 10/20 33.7 % 1.50 [ 0.90, 2.49 ]
Total (95% CI) 98 91 100.0 % 1.54 [ 1.00, 2.37 ]
Total events: 65 (Duodenum preserving), 41 (Pancreaticoduodenectomy)
Heterogeneity: Tau2 = 0.08; Chi2 = 5.28, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours panc duodenectomy Favours duo preserving
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Analysis 1.9. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 9 New-onset diabetes.
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome: 9 New-onset diabetes
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buchler 1995 7/20 11/20 33.8 % 0.64 [ 0.31, 1.30 ]
Farkas 2006 0/20 3/20 10.8 % 0.14 [ 0.01, 2.60 ]
Izbicki 1998 8/31 4/30 12.5 % 1.94 [ 0.65, 5.76 ]
Keck 2012 8/42 10/43 30.4 % 0.82 [ 0.36, 1.87 ]
Klempa 1995 2/22 4/21 12.6 % 0.48 [ 0.10, 2.34 ]
Total (95% CI) 135 134 100.0 % 0.78 [ 0.50, 1.22 ]
Total events: 25 (Duodenum preserving), 32 (Pancreaticoduodenectomy)
Heterogeneity: Chi2 = 4.67, df = 4 (P = 0.32); I2 =14%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy,
Outcome 10 Pancreatic exocrine insufficiency.
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 1 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
Outcome: 10 Pancreatic exocrine insufficiency
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Buchler 1995 8/15 8/14 11.6 % 0.93 [ 0.48, 1.80 ]
Izbicki 1998 18/21 13/14 22.0 % 0.92 [ 0.74, 1.16 ]
Keck 2012 32/42 27/43 37.5 % 1.21 [ 0.91, 1.61 ]
Klempa 1995 4/20 20/20 28.8 % 0.22 [ 0.10, 0.50 ]
Total (95% CI) 98 91 100.0 % 0.83 [ 0.68, 1.02 ]
Total events: 62 (Duodenum preserving), 68 (Pancreaticoduodenectomy)
Heterogeneity: Chi2 = 17.81, df = 3 (P = 0.00048); I2 =83%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
(subgroup analysis), Outcome 1 Short-term mortality.
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 2 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy (subgroup analysis)
Outcome: 1 Short-term mortality
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beger procedure vs. Whipple procedure
Buchler 1995 0/20 0/20 Not estimable
Klempa 1995 1/22 0/21 50.2 % 2.87 [ 0.12, 66.75 ]
Subtotal (95% CI) 42 41 50.2 % 2.87 [ 0.12, 66.75 ]
Total events: 1 (Duodenum preserving), 0 (Pancreaticoduodenectomy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Frey procedure vs. pylorus-preserving pancreaticoduodenectomy
Izbicki 1998 1/31 0/30 49.8 % 2.91 [ 0.12, 68.66 ]
Subtotal (95% CI) 31 30 49.8 % 2.91 [ 0.12, 68.66 ]
Total events: 1 (Duodenum preserving), 0 (Pancreaticoduodenectomy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
3 Wide local excision of head of pancreas vs. pylorus-preserving pancreaticoduodenectomy
Farkas 2006 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Duodenum preserving), 0 (Pancreaticoduodenectomy)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 93 91 100.0 % 2.89 [ 0.31, 26.87 ]
Total events: 2 (Duodenum preserving), 0 (Pancreaticoduodenectomy)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
Favours duo preserving Favours panc duodenectomy
42Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
(subgroup analysis), Outcome 2 Long-term mortality.
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 2 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy (subgroup analysis)
Outcome: 2 Long-term mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Beger procedure vs. Whipple procedure
Buchler 1995 0.216633 (0.32197) 31.8 % 1.24 [ 0.66, 2.33 ]
Klempa 1995 0 (0.616441) 9.0 % 1.00 [ 0.30, 3.35 ]
Subtotal (95% CI) 40.8 % 1.19 [ 0.68, 2.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Frey procedure vs. pylorus-preserving pancreaticoduodenectomy
Izbicki 1998 -0.34813 (0.229911) 59.2 % 0.71 [ 0.45, 1.11 ]
Subtotal (95% CI) 59.2 % 0.71 [ 0.45, 1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 100.0 % 0.87 [ 0.60, 1.26 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Chi2 = 2.00, df = 1 (P = 0.16), I2 =50%
0.01 0.1 1 10 100
Favours duo preserving Favours panc duodenectomy
Analysis 2.3. Comparison 2 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
(subgroup analysis), Outcome 3 Quality of life (3 months to 1 year).
Quality of life (3 months to 1 year)
Study Quality of life scale used
and time of measurement
Median score in duode-
num preserving pancre-
atic resection group
Me-
dian score in pancreatico-
duodenectomy group
Statistical significance
Frey procedure vs. pylorus-preserving pancreaticoduodenectomy
Izbicki 1998 EORTC QLQ-C30 global
health status (higher scores
indicate better quality of
life); median follow-up 24
months (range 12 months
to 36 months)
85.7 28.6 Not reported
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Analysis 2.4. Comparison 2 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy
(subgroup analysis), Outcome 4 Quality of life (> 5 years).
Review: Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis
Comparison: 2 Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy (subgroup analysis)
Outcome: 4 Quality of life (> 5 years)
Study or subgroup
Duodenum
preserving Pancreaticoduodenectomy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Beger procedure vs. Whipple procedure
Buchler 1995 20 65 (22.3) 20 58.3 (34.2) 23.8 % 6.70 [ -11.19, 24.59 ]
Subtotal (95% CI) 20 20 23.8 % 6.70 [ -11.19, 24.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 Frey procedure vs. pylorus-preserving pancreaticoduodenectomy
Izbicki 1998 31 67 (19.9) 30 58 (19.9) 76.2 % 9.00 [ -0.99, 18.99 ]
Subtotal (95% CI) 31 30 76.2 % 9.00 [ -0.99, 18.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Total (95% CI) 51 50 100.0 % 8.45 [ -0.27, 17.18 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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A P P E N D I C E S
Appendix 1. Glossary of terms
Acute: sudden.
Adverse events: side effects.
Aetiology: cause of a disease.
Analogue: (in this context) a chemical compound that is structurally similar to a naturally occurring hormone.
Anastomoses: plural for anastomosis or ’joining’ two or more structures.
American Society of Anesthesiologists (ASA) status: likelihood of someone developing complications following surgery based on the
current health status of a person.
Antioxidants: (in this context) a chemical that prevents the damaging effects of chemicals released during oxidation.
Autoimmune: disease caused by the body’s defensive mechanism against infections reacting against and damaging body’s own tissues.
Biliary enteric anastomosis: joining the biliary tract (structure which carries bile) and the small bowel.
Biliary obstruction: blockage to flow of bile.
Biopsy: examination of a piece of tissue removed from a living body.
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Caerulein: a hormone that has a similar action to cholecystokinin (see below).
Calcifications: calcium deposits in tissue.
CFTR mutation: alteration in the genetic code for a protein called cystic fibrosis transport regulator (CFTR).
Cholecystokinin: a hormone that increases the contractility of the gallbladder thus increasing the flow of bile into the small bowel.
Chronic: long-standing.
Coeliac plexus block: injection of long-acting local anaesthetic into the coeliac plexus, a network of nerves that supply the abdominal
organs.
Computed tomography: CT scan. This is performed by taking a series of X-rays using special equipment and processing the images
using a computer to obtain a final image.
Diabetes: a lifelong condition that causes a person’s blood sugar level to become too high.
Digestive enzyme deficiency: shortage of enzymes that help with digestion by breaking down the food that we eat into substances
that can be absorbed from the gut.
Duodenal aspirate: fluid obtained from the upper part of the small intestine usually with a tube inserted into the small intestine
through the nose or mouth.
Duodenum: upper part of the small bowel. It conducts digested food from the stomach to themiddle part of the small bowel (jejunum).
The bile duct and the pancreatic duct conduct the bile and pancreatic juice drain into the duodenum.
Elastase: enzyme that breaks down protein.
Endocrine pancreatic insufficiency: deficiency of hormones secreted from cells in the pancreas, clinically manifesting as diabetes
because of insulin deficiency.
Endoscopic retrograde cholangio pancreatography: a diagnostic test that involves the use of an endoscope and X-rays to image the
pancreas and biliary system.
Endoscopic ultrasound: an ultrasound scan that is performed using an endoscope.
Enteric: small bowel.
Excised: surgically removed.
Exocrine pancreatic insufficiency: deficiency of pancreatic digestive enzymes.
Fistula: an abnormal or surgically made passage between a hollow or tubular organ and the body surface, or between two hollow or
tubular organs.
Flatulence: excessive wind.
Gastro-enteric anastomosis: joining the stomach to the small bowel.
Histopathological examination: examination under microscope.
Hypercalcaemia: high calcium in blood.
Hyperparathyroidism: high parathyroid hormone (a hormone involved in maintaining calcium level) in blood.
Hypertension: high blood pressure.
Idiopathic: cause of disease could not be identified.
Insulin: substance that helps regulate blood sugar.
Jaundice: yellowish discolouration of the whites of the eyes, skin, and inner linings of the mouth caused usually by liver diseases or
obstruction to the flow of bile from liver into small bowel.
Jejunum: second part of small bowel.
Mortality: death.
Neural: nerve-related.
Neurolysis: destruction of nerve (in this context, using injection of chemicals such as 100% alcohol (absolute alcohol) or by heat
generated by radiofrequency waves).
Oestrogens: hormones that promote the development and maintenance of female characteristics of the body. Such hormones are also
produced artificially for use in oral contraceptives or to treat menopausal and menstrual disorders.
Oxidative damage: (in this context) damage due to oxidation, which releases chemicals that cause damage to tissues.
Pancreatic enzyme supplementation: providing pancreatic enzymes.
Pancreatic pseudocysts: fluid collections in the pancreas or the tissues surrounding the pancreas, surrounded by a well-defined wall
and containing only fluid with little or no solid material.
Parenchyma: the essential element of the organ as opposed to the supporting tissue.
Pathogenesis: development of a disease.
Peripancreatic: around the pancreas.
Pregabalin: a medicine used for seizures and for pain, which is considered to be due to excessive nerve stimulation.
Pylorus: part of the stomach that connects the stomach to the duodenum.
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Renal: kidney.
Secretin-enhanced magnetic resonance cholangiopancreatography: a magnetic resonance scan (MRI) done after administering
secretin (a hormone that regulates the secretion of the stomach and pancreas).
Sensory fibres: nerve fibres that carry the sensations including pain.
Somatostatin analogue: a chemical with similar action to somatostatin, which is a hormone that decreases stomach and pancreatic
secretions.
SPINK 1 mutation: alteration in the genetic code for a protein called serine protease inhibitor Kazal-type 1 (SPINK 1).
Steatorrhoea: bulky, foul-smelling stools due to the presence of excessive fat in the stools.
Stenosis: narrowing.
Surgical excision: surgical removal.
Sympathetic fibres: nerve fibres that control involuntary actions in the body such as control of blood pressure.
Thiazide: a medicine used to lower blood pressure by increasing the excretion of salt and water from body.
Valproate: a medicine used in people with epilepsy.
Visual analogue scale: (in this context) a measurement tool to compare subjective measures such as pain that cannot be directly
measured; the respondents specify their pain level along a continuous line between 0 and 10 or 0 and 100.
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor: [Pancreatitis, Chronic] explode all trees
#2 chronic pancreatitis
#3 #1 or #2
#4 MeSH descriptor: [Pancreaticoduodenectomy] explode all trees
#5 MeSH descriptor: [Pancreatectomy] explode all trees
#6 pancreaticoduodenectomy or pancreaticoduodenectomies or duodenopancreatectomy or duodenopancreatectomies or pancreatec-
tomy
#7 #4 or #5 or #6
#8 #3 and #7
Appendix 3. MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Pancreatitis, Chronic/
13. chronic pancreatitis.mp.
14. 12 or 13
15. exp Pancreaticoduodenectomy/
16. exp Pancreatectomy/
17. (pancreaticoduodenectomy or pancreaticoduodenectomies or duodenopancreatectomy or duodenopancreatectomies or pancreate-
ctomy).mp.
18. 15 or 16 or 17
19. 11 and 14 and 18
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Appendix 4. EMBASE search strategy
1. Clinical trial/
2. Randomized controlled trial/
3. Randomization/
4. Single-Blind Method/
5. Double-Blind Method/
6. Cross-Over Studies/
7. Random Allocation/
8. Placebo/
9. Randomi?ed controlled trial*.tw.
10. Rct.tw.
11. Random allocation.tw.
12. Randomly allocated.tw.
13. Allocated randomly.tw.
14. (allocated adj2 random).tw.
15. Single blind*.tw.
16. Double blind*.tw.
17. ((treble or triple) adj blind*).tw.
18. Placebo*.tw.
19. Prospective study/
20. or/1-19
21. Case study/
22. Case report.tw.
23. Abstract report/ or letter/
24. or/21-23
25. 20 not 24
26. exp Pancreatitis, Chronic/
27. chronic pancreatitis.mp.
28. 26 or 27
29. exp pancreaticoduodenectomy/
30. exp pancreas resection/
31. (pancreaticoduodenectomy or pancreaticoduodenectomies or duodenopancreatectomy or duodenopancreatectomies or pancreate-
ctomy).mp.
32. 29 or 30 or 31
33. 25 and 28 and 32
Appendix 5. Science Citation Index search strategy
# 1 TS=(chronic pancreatitis)
# 2 TS=(pancreaticoduodenectomy or pancreaticoduodenectomies or duodenopancreatectomy or duodenopancreatectomies or pan-
createctomy)
# 3 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-
analys*)
# 4 #3 AND #2 AND #1
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Appendix 6. ClinicalTrials.gov search strategy
Interventional Studies | chronic pancreatitis | pancreaticoduodenectomy | Phase 2, 3, 4
Appendix 7. WHO ICTRP search strategy
chronic pancreatitis AND pancreaticoduodenectomy
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. We added long-term mortality to the list of primary outcomes. Although we anticipated only short-term differences between the
treatments compared, we recognised that the interventions may have long-term effects on mortality as well. Clearly, this is an
important patient-oriented outcome.
2. We added proportion of people at work at maximal follow-up to the list of secondary outcomes. Although we anticipated only
short-term differences between the treatments compared in terms of return to work, we recognised that the interventions may have
long-term effects on the ability to work as well. Clearly, this is an important patient-oriented outcome.
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